https://trial.medpath.com/news/ai-and-biomarkers-drive-precision-medicine-evolution-industry-experts-predict-54b-gene-therapy-market-by-2029 2023-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-and-biomarkers-drive-precision-medicine-evolution-industry-experts-predict-54b-gene-therapy-market-by-2029 2023-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-durvalumab-plus-chemotherapy-significantly-improves-outcomes-in-resectable-non-small-cell-lung-cancer 2023-10-23T12:46:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perioperative-durvalumab-plus-chemotherapy-significantly-improves-outcomes-in-resectable-non-small-cell-lung-cancer 2023-10-23T12:46:11+00:00 weekly 0.7 https://trial.medpath.com/news/nervgen-pharma-receives-fast-track-designation-for-nvg-291-in-spinal-cord-injury-treatment 2023-10-23T12:31:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nervgen-pharma-receives-fast-track-designation-for-nvg-291-in-spinal-cord-injury-treatment 2023-10-23T12:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/dostarlimab-shows-superior-survival-outcomes-across-multiple-endometrial-cancer-molecular-subgroups-in-phase-3-ruby-trial 2023-10-23T01:32:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dostarlimab-shows-superior-survival-outcomes-across-multiple-endometrial-cancer-molecular-subgroups-in-phase-3-ruby-trial 2023-10-23T01:32:00+00:00 weekly 0.7 https://trial.medpath.com/news/verve-therapeutics-announces-clearance-of-investigational-new-drug-application-by-the-u-s-fda-for-verve-101-in-patients-with-heterozygous-familial-hypercholesterolemia 2023-10-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verve-therapeutics-announces-clearance-of-investigational-new-drug-application-by-the-u-s-fda-for-verve-101-in-patients-with-heterozygous-familial-hypercholesterolemia 2023-10-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-pluvictotm-shows-clinically-meaningful-and-highly 2023-10-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-pluvictotm-shows-clinically-meaningful-and-highly 2023-10-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-bispecific-immunotherapy-shows-promise-across-multiple-cancer-types-in-early-clinical-trial 2023-10-19T15:13:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-bispecific-immunotherapy-shows-promise-across-multiple-cancer-types-in-early-clinical-trial 2023-10-19T15:13:10+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-daiichi-sankyo-form-22-billion-alliance-for-three-novel-antibody-drug-conjugates 2023-10-19T04:41:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-and-daiichi-sankyo-form-22-billion-alliance-for-three-novel-antibody-drug-conjugates 2023-10-19T04:41:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-rise-therapeutics-ind-application-to-initiate-a-phase-1 2023-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-rise-therapeutics-ind-application-to-initiate-a-phase-1 2023-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cilta-cel-leads-to-high-pfs-rates-in-patients-with-multiple-myeloma 2023-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cilta-cel-leads-to-high-pfs-rates-in-patients-with-multiple-myeloma 2023-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-reports-positive-long-term-data-for-alfapump-in-treating-ascites 2023-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-reports-positive-long-term-data-for-alfapump-in-treating-ascites 2023-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bimzelx-r-approved-by-the-u-s-fda-for-the-treatment-of-adults-with 2023-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bimzelx-r-approved-by-the-u-s-fda-for-the-treatment-of-adults-with 2023-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/traverse-biotech-has-been-awarded-a-phase-i-sbir-grant-from-the-national-cancer-institute-to-develop-targeted-immunotherapy-for-selected-solid-tumors-biospace 2023-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/traverse-biotech-has-been-awarded-a-phase-i-sbir-grant-from-the-national-cancer-institute-to-develop-targeted-immunotherapy-for-selected-solid-tumors-biospace 2023-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-seastar-medical-s-selective-cytopheretic-device-breakthrough-device-designation-for-hepatorenal-syndrome 2023-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-seastar-medical-s-selective-cytopheretic-device-breakthrough-device-designation-for-hepatorenal-syndrome 2023-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-new-real-world-data-guidance-streamlining-drug-development-and-regulatory-approval 2023-10-17T14:06:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-new-real-world-data-guidance-streamlining-drug-development-and-regulatory-approval 2023-10-17T14:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/nucleus-radiopharma-secures-56m-series-a-to-expand-radiopharmaceutical-manufacturing-network 2023-10-17T10:06:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nucleus-radiopharma-secures-56m-series-a-to-expand-radiopharmaceutical-manufacturing-network 2023-10-17T10:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-to-offer-new-curative-treatment-for-aggressive-blood-cancer 2023-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-to-offer-new-curative-treatment-for-aggressive-blood-cancer 2023-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-receives-fda-clearance-of-tactiflextm-ablation 2023-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbott-receives-fda-clearance-of-tactiflextm-ablation 2023-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/concept-medical-received-fda-ide-approval-for 2023-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/concept-medical-received-fda-ide-approval-for 2023-10-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sillajen-presents-clinical-study-overview-of-anticancer-drug-bal0891-at-international-symposium 2023-10-16T16:11:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sillajen-presents-clinical-study-overview-of-anticancer-drug-bal0891-at-international-symposium 2023-10-16T16:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-nivolumab-shows-significant-benefit-in-resected-stage-iib-c-melanoma 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adjuvant-nivolumab-shows-significant-benefit-in-resected-stage-iib-c-melanoma 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immix-biopharma-completes-3rd-nxc-201-engineering-batch-at-its-u-s-car-t-manufacturing-site-markets-insider 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immix-biopharma-completes-3rd-nxc-201-engineering-batch-at-its-u-s-car-t-manufacturing-site-markets-insider 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tilray-medical-supports-new-clinical-trial-to-study-medical-cannabis-in-glioblastoma-cancer-treatment 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tilray-medical-supports-new-clinical-trial-to-study-medical-cannabis-in-glioblastoma-cancer-treatment 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-mrna-based-cancer-vaccines 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-in-mrna-based-cancer-vaccines 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-announces-opening-of-tigris-clinical-trial-site-at-the-mayo-clinic-markets-insider 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-medical-announces-opening-of-tigris-clinical-trial-site-at-the-mayo-clinic-markets-insider 2023-10-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-ventilation-strategies-on-pulmonary-and-cardiovascular 2023-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-of-ventilation-strategies-on-pulmonary-and-cardiovascular 2023-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/brain-tumor-center-stanford-medicine 2023-10-12T12:57:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brain-tumor-center-stanford-medicine 2023-10-12T12:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/cap-1002-parent-project-muscular-dystrophy 2023-10-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cap-1002-parent-project-muscular-dystrophy 2023-10-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intranasal-epinephrine-spray-shows-superior-pharmacokinetics-to-autoinjector-in-anaphylaxis-treatment-study 2023-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intranasal-epinephrine-spray-shows-superior-pharmacokinetics-to-autoinjector-in-anaphylaxis-treatment-study 2023-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/south-korea-positions-life-sciences-sector-for-global-leadership-with-strategic-five-point-plan 2023-10-10T21:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/south-korea-positions-life-sciences-sector-for-global-leadership-with-strategic-five-point-plan 2023-10-10T21:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/crinecerfont-shows-promise-in-treating-children-with-congenital-adrenal-hyperplasia 2023-10-10T16:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crinecerfont-shows-promise-in-treating-children-with-congenital-adrenal-hyperplasia 2023-10-10T16:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/cuba-advances-phase-iii-clinical-trial-of-jusvinza-for-rheumatoid-arthritis-treatment 2023-10-09T15:25:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cuba-advances-phase-iii-clinical-trial-of-jusvinza-for-rheumatoid-arthritis-treatment 2023-10-09T15:25:05+00:00 weekly 0.7 https://trial.medpath.com/news/analysis-of-sodium-phenylbutyrate-and-taurursodiol 2023-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/analysis-of-sodium-phenylbutyrate-and-taurursodiol 2023-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rg6501-shows-rapid-improvement-in-retinal-structure-for-geographic-atrophy-patients 2023-10-08T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rg6501-shows-rapid-improvement-in-retinal-structure-for-geographic-atrophy-patients 2023-10-08T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/paradigm-and-bristol-myers-squibb-collaborate-to-build-a-new-model-for-clinical-trials 2023-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paradigm-and-bristol-myers-squibb-collaborate-to-build-a-new-model-for-clinical-trials 2023-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-panel-votes-sufficient-evidence-available-to-support 2023-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-panel-votes-sufficient-evidence-available-to-support 2023-10-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/landmark-uk-biobank-study-reveals-14000-novel-gene-protein-interactions-to-transform-drug-discovery 2023-10-05T02:20:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/landmark-uk-biobank-study-reveals-14000-novel-gene-protein-interactions-to-transform-drug-discovery 2023-10-05T02:20:26+00:00 weekly 0.7 https://trial.medpath.com/news/expanded-access-programs-bridging-the-gap-between-clinical-trials-and-patient-need 2023-10-04T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expanded-access-programs-bridging-the-gap-between-clinical-trials-and-patient-need 2023-10-04T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-wegovy-improve-blood-sugar-control-and-weight-loss-over-3-years-study-finds 2023-10-03T14:38:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-wegovy-improve-blood-sugar-control-and-weight-loss-over-3-years-study-finds 2023-10-03T14:38:13+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-acquires-point-biopharma-for-1-4-billion-to-expand-radioligand-therapy-portfolio 2023-10-03T05:21:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-acquires-point-biopharma-for-1-4-billion-to-expand-radioligand-therapy-portfolio 2023-10-03T05:21:48+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-2023-2024-covid-19-vaccine-authorized-for-emergency-use-in-the-u-s 2023-10-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novavax-2023-2024-covid-19-vaccine-authorized-for-emergency-use-in-the-u-s 2023-10-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/valbiotis-sa-phase-ii-iii-reverse-it-study-to-be-presented-at-2023-easd-congress 2023-10-02T17:42:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valbiotis-sa-phase-ii-iii-reverse-it-study-to-be-presented-at-2023-easd-congress 2023-10-02T17:42:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-greenlights-alzamend-neuro-s-phase-iia-trial-of-novel-lithium-therapy-al001-for-bipolar-disorder 2023-10-02T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-greenlights-alzamend-neuro-s-phase-iia-trial-of-novel-lithium-therapy-al001-for-bipolar-disorder 2023-10-02T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-moves-advancement-prospects-plunge-for-parkinsons 2023-10-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pipeline-moves-advancement-prospects-plunge-for-parkinsons 2023-10-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapies-for-diffuse-midline-glioma-sciencedirect 2023-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapies-for-diffuse-midline-glioma-sciencedirect 2023-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-immune-checkpoint-inhibition-for-hepatocellular-carcinoma-treatment 2023-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-immune-checkpoint-inhibition-for-hepatocellular-carcinoma-treatment 2023-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nxc-201-demonstrates-feasibility-of-bcma-directed-car-t-cell-therapy-in-relapsed-refractory-al-amyloidosis 2023-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nxc-201-demonstrates-feasibility-of-bcma-directed-car-t-cell-therapy-in-relapsed-refractory-al-amyloidosis 2023-09-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-exxua-a-novel-antidepressant-for-major-depressive-disorder 2023-09-28T09:07:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-exxua-a-novel-antidepressant-for-major-depressive-disorder 2023-09-28T09:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/akebia-therapeutics-resubmits-new-drug-application-to-the-fda-for-vadadustat 2023-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akebia-therapeutics-resubmits-new-drug-application-to-the-fda-for-vadadustat 2023-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-emergency-use-authorization-for-evusheld 2023-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-revokes-emergency-use-authorization-for-evusheld 2023-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-cancer-drug-combo-beats-tagrisso-in-closely-watched-trial 2023-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-cancer-drug-combo-beats-tagrisso-in-closely-watched-trial 2023-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bosutinib-for-pediatric-chronic-myelogenous-leukemia-patients 2023-09-27T18:39:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-bosutinib-for-pediatric-chronic-myelogenous-leukemia-patients 2023-09-27T18:39:45+00:00 weekly 0.7 https://trial.medpath.com/news/viva-s-portfolio-companies-announce-significant-advances-in-biopharmaceutical-innovations 2023-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viva-s-portfolio-companies-announce-significant-advances-in-biopharmaceutical-innovations 2023-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/unity-biotechnology-announces-48-week-results-from-phase-2-envision-study-of-ubx1325-in-patients-with-wet-age-related-macular-degeneration 2023-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unity-biotechnology-announces-48-week-results-from-phase-2-envision-study-of-ubx1325-in-patients-with-wet-age-related-macular-degeneration 2023-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/amphista-therapeutics-hits-second-milestone-in-bristol-myers-squibb-protein-degradation-partnership 2023-09-26T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amphista-therapeutics-hits-second-milestone-in-bristol-myers-squibb-protein-degradation-partnership 2023-09-26T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/actinogen-optimizes-xanamia-phase-2b-alzheimer-s-disease-trial-design 2023-09-26T12:56:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actinogen-optimizes-xanamia-phase-2b-alzheimer-s-disease-trial-design 2023-09-26T12:56:06+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-starts-the-pivotal-clinical-trial-for-axess 2023-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xeltis-starts-the-pivotal-clinical-trial-for-axess 2023-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-receives-orphan-drug-designation-odd-for-resminostat-kinselby 2023-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4sc-receives-orphan-drug-designation-odd-for-resminostat-kinselby 2023-09-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-targets-and-strategic-sequencing-the-evolving-landscape-of-t-cell-redirection-therapies-in-multiple-myeloma 2023-09-22T13:00:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-targets-and-strategic-sequencing-the-evolving-landscape-of-t-cell-redirection-therapies-in-multiple-myeloma 2023-09-22T13:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-hasten-tool-accelerates-virtual-drug-screening-10-fold 2023-09-22T02:31:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-powered-hasten-tool-accelerates-virtual-drug-screening-10-fold 2023-09-22T02:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/leucid-bio-s-lateral-nkg2d-car-t-therapy-leu011-receives-mhra-approval-for-solid-tumor-clinical-trial 2023-09-21T03:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leucid-bio-s-lateral-nkg2d-car-t-therapy-leu011-receives-mhra-approval-for-solid-tumor-clinical-trial 2023-09-21T03:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/drug-for-rare-kidney-disease-narrowly-misses-mark-in-clinical-trial 2023-09-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-for-rare-kidney-disease-narrowly-misses-mark-in-clinical-trial 2023-09-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-approves-orphan-drug-designation-for-immix-biopharma-nxc-201-as-a-treatment-for-amyloid-light-chain-al-amyloidosis-september-21-2023-at-08-56-am-edt-marketscreener 2023-09-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-food-and-drug-administration-approves-orphan-drug-designation-for-immix-biopharma-nxc-201-as-a-treatment-for-amyloid-light-chain-al-amyloidosis-september-21-2023-at-08-56-am-edt-marketscreener 2023-09-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-roactemra-biosimilar-tyenne-receives-eu-approval-marking-milestone-for-fresenius-kabi 2023-09-20T02:55:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-roactemra-biosimilar-tyenne-receives-eu-approval-marking-milestone-for-fresenius-kabi 2023-09-20T02:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/extended-course-nirmatrelvir-ritonavir-shows-promise-in-treating-long-covid-symptoms 2023-09-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/extended-course-nirmatrelvir-ritonavir-shows-promise-in-treating-long-covid-symptoms 2023-09-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musks-neuralink-recruiting-humans-to-trial-brain-implant 2023-09-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musks-neuralink-recruiting-humans-to-trial-brain-implant 2023-09-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/translarna-approval-for-dmd-in-eu-not-recommended-for-renewal-therapy-developer-ptc-to-seek-new-review-by-ema-committee-muscular-dystrophy-news 2023-09-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/translarna-approval-for-dmd-in-eu-not-recommended-for-renewal-therapy-developer-ptc-to-seek-new-review-by-ema-committee-muscular-dystrophy-news 2023-09-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cloud-based-data-analytics-emerges-as-key-driver-for-life-sciences-innovation-and-drug-development 2023-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cloud-based-data-analytics-emerges-as-key-driver-for-life-sciences-innovation-and-drug-development 2023-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genetically-modified-pig-kidney-functions-for-61-days-in-human-body-setting-xenotransplantation-record 2023-09-14T15:01:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genetically-modified-pig-kidney-functions-for-61-days-in-human-body-setting-xenotransplantation-record 2023-09-14T15:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-s-phase-2b-3-trial-of-blarcamesine-shows-promising-results-in-alzheimer-s-disease-treatment 2023-09-14T11:30:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anavex-s-phase-2b-3-trial-of-blarcamesine-shows-promising-results-in-alzheimer-s-disease-treatment 2023-09-14T11:30:11+00:00 weekly 0.7 https://trial.medpath.com/news/axicabtagene-ciloleucel-as-second-line-therapy-in-large-b-cell-lymphoma 2023-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/axicabtagene-ciloleucel-as-second-line-therapy-in-large-b-cell-lymphoma 2023-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/game-changing-alzheimer-s-drugs-could-drive-a-wave-of 2023-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/game-changing-alzheimer-s-drugs-could-drive-a-wave-of 2023-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-s-combo-covid-19-and-flu-vaccine-shows-promising-results-in-early-trial 2023-09-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-s-combo-covid-19-and-flu-vaccine-shows-promising-results-in-early-trial 2023-09-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-skyrizi-r-risankizumab-met-all-primary-and-secondary-endpoints-versus-stelara-r-ustekinumab-in-head-to-head-study-in-crohn-s-disease 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-skyrizi-r-risankizumab-met-all-primary-and-secondary-endpoints-versus-stelara-r-ustekinumab-in-head-to-head-study-in-crohn-s-disease 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/izokibep-fails-in-phase-2b-3-hidradenitis-suppurativa-trial 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/izokibep-fails-in-phase-2b-3-hidradenitis-suppurativa-trial 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-plummets-on-skin-disease-trial-schaeffer-s-investment-research 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-stock-plummets-on-skin-disease-trial-schaeffer-s-investment-research 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-nasdaq-slrn-plummets-on-disappointing-hs-trial-results-tipranks-com 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-nasdaq-slrn-plummets-on-disappointing-hs-trial-results-tipranks-com 2023-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-updated-covid-vaccines-from-pfizer-and-moderna-as 2023-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-updated-covid-vaccines-from-pfizer-and-moderna-as 2023-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-alzheimer-s-disease-treatment-a-focus-on-disease-modifying-therapies 2023-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-in-alzheimer-s-disease-treatment-a-focus-on-disease-modifying-therapies 2023-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotech-faces-steep-decline-bank-of-america-warns 2023-09-08T14:38:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotech-faces-steep-decline-bank-of-america-warns 2023-09-08T14:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/ariceum-therapeutics-doses-first-patient-in-phase-ib-study-for-small-cell-lung-cancer-treatment 2023-09-07T08:00:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ariceum-therapeutics-doses-first-patient-in-phase-ib-study-for-small-cell-lung-cancer-treatment 2023-09-07T08:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/application-to-market-givinostat-for-dmd-in-europe-under 2023-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/application-to-market-givinostat-for-dmd-in-europe-under 2023-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-inc-closes-c-6-1-million-bought-deal-convertible-note-financing-the-globe-and-mail 2023-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-medical-inc-closes-c-6-1-million-bought-deal-convertible-note-financing-the-globe-and-mail 2023-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/retail-pharmacies-are-working-with-pharmaceutical-companies-to 2023-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/retail-pharmacies-are-working-with-pharmaceutical-companies-to 2023-09-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bispecific-t-cell-engagers-show-promise-as-later-line-therapies-for-relapsed-refractory-dlbcl 2023-09-06T19:00:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bispecific-t-cell-engagers-show-promise-as-later-line-therapies-for-relapsed-refractory-dlbcl 2023-09-06T19:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/cingulate-s-phase-3-trial-shows-promising-results-for-once-daily-adhd-treatment-ctx-1301 2023-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cingulate-s-phase-3-trial-shows-promising-results-for-once-daily-adhd-treatment-ctx-1301 2023-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-2-activate-trial-of-bia-28-6156-for 2023-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-phase-2-activate-trial-of-bia-28-6156-for 2023-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/olema-oncology-secures-up-to-180-million-in-combined-financing 2023-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olema-oncology-secures-up-to-180-million-in-combined-financing 2023-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nestle-divests-palforzia-to-stallergenes-greer-exits-peanut-allergy-treatment-market 2023-09-04T02:53:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nestle-divests-palforzia-to-stallergenes-greer-exits-peanut-allergy-treatment-market 2023-09-04T02:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/denosumab-biosimilar-ly01011-demonstrates-bioequivalence-in-phase-1-trial 2023-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/denosumab-biosimilar-ly01011-demonstrates-bioequivalence-in-phase-1-trial 2023-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mpn-628-surpass-et-ropeginterferon-alfa-2b-p1101 2023-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mpn-628-surpass-et-ropeginterferon-alfa-2b-p1101 2023-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intraventricular-b7-h3-car-t-cells-for-diffuse-intrinsic 2023-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intraventricular-b7-h3-car-t-cells-for-diffuse-intrinsic 2023-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-launches-phase-3-trial-testing-elranatamab-triple-combination-for-newly-diagnosed-multiple-myeloma 2023-08-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-launches-phase-3-trial-testing-elranatamab-triple-combination-for-newly-diagnosed-multiple-myeloma 2023-08-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-outlook-therapeutics-wet-amd-drug-due-to-manufacturing-issues-and-insufficient-clinical-evidence 2023-08-30T13:17:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rejects-outlook-therapeutics-wet-amd-drug-due-to-manufacturing-issues-and-insufficient-clinical-evidence 2023-08-30T13:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-names-first-10-drugs-for-price-negotiations-including-major-diabetes-and-cancer-therapies 2023-08-29T05:43:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicare-names-first-10-drugs-for-price-negotiations-including-major-diabetes-and-cancer-therapies 2023-08-29T05:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/bluerock-s-phase-i-study-with-bemdaneprocel-in-parkinson-s-disease-meets-primary-endpoint 2023-08-28T10:30:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bluerock-s-phase-i-study-with-bemdaneprocel-in-parkinson-s-disease-meets-primary-endpoint 2023-08-28T10:30:16+00:00 weekly 0.7 https://trial.medpath.com/news/merck-launches-first-phase-3-program-for-oral-pcsk9-inhibitor-mk-0616-to-treat-high-cholesterol 2023-08-25T06:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-launches-first-phase-3-program-for-oral-pcsk9-inhibitor-mk-0616-to-treat-high-cholesterol 2023-08-25T06:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/synapticure-on-science-clinical-trials-for-sporadic-als 2023-08-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synapticure-on-science-clinical-trials-for-sporadic-als 2023-08-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lipid-nanoparticles-demonstrate-complex-immunological-effects-in-mrna-vaccine-delivery 2023-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lipid-nanoparticles-demonstrate-complex-immunological-effects-in-mrna-vaccine-delivery 2023-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-revolution-in-pharma-transforming-drug-development-to-patient-care 2023-08-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-revolution-in-pharma-transforming-drug-development-to-patient-care 2023-08-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genesis-therapeutics-secures-200m-series-b-to-advance-ai-powered-drug-discovery-platform 2023-08-21T12:46:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genesis-therapeutics-secures-200m-series-b-to-advance-ai-powered-drug-discovery-platform 2023-08-21T12:46:52+00:00 weekly 0.7 https://trial.medpath.com/news/study-protocol-of-the-launch-3-trial-comparing-laparoscopic-and-abdominal-radical-hysterectomy-for-cervical-cancer 2023-08-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-protocol-of-the-launch-3-trial-comparing-laparoscopic-and-abdominal-radical-hysterectomy-for-cervical-cancer 2023-08-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/yale-researchers-develop-polymer-nanoparticles-for-effective-mrna-delivery-to-lungs 2023-08-16T19:00:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yale-researchers-develop-polymer-nanoparticles-for-effective-mrna-delivery-to-lungs 2023-08-16T19:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-receives-fda-approval-for-generic-bromfenac-ophthalmic-solution-for-post-cataract-surgery-treatment 2023-08-16T15:43:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lupin-receives-fda-approval-for-generic-bromfenac-ophthalmic-solution-for-post-cataract-surgery-treatment 2023-08-16T15:43:00+00:00 weekly 0.7 https://trial.medpath.com/news/immix-announces-additional-nxc-201-al-amyloidosis-data-to-be-presented-tipranks-com 2023-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immix-announces-additional-nxc-201-al-amyloidosis-data-to-be-presented-tipranks-com 2023-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-clear-study-shows-improved-efficacy-of-lenvatinib-plus-pembrolizumab-in-advanced-renal-cell-carcinoma 2023-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-clear-study-shows-improved-efficacy-of-lenvatinib-plus-pembrolizumab-in-advanced-renal-cell-carcinoma 2023-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-second-line-axi-cel-for-dlbcl-hgbl-onclive 2023-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-approves-second-line-axi-cel-for-dlbcl-hgbl-onclive 2023-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-regulators-recommend-cabometyx-for-radioactive-iodine-refractory-thyroid-cancer-based-on-78-reduction-in-disease-progression 2023-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-regulators-recommend-cabometyx-for-radioactive-iodine-refractory-thyroid-cancer-based-on-78-reduction-in-disease-progression 2023-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-reports-second-quarter-2023-financial 2023-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-inc-reports-second-quarter-2023-financial 2023-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-axess-vascular-graft-development-receives-funding-from-european 2023-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xeltis-axess-vascular-graft-development-receives-funding-from-european 2023-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-drug-wegovy-cuts-heart-attack-risk-in-people-with-obesity-study-shows 2023-08-08T19:04:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-loss-drug-wegovy-cuts-heart-attack-risk-in-people-with-obesity-study-shows 2023-08-08T19:04:51+00:00 weekly 0.7 https://trial.medpath.com/news/asco-s-guideline-rapid-recommendation-update-for-esr1-mutation-testing 2023-08-08T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asco-s-guideline-rapid-recommendation-update-for-esr1-mutation-testing 2023-08-08T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-veteran-receives-fda-approved-qalsody-for-sod1-als-at-houston-va-medical-center 2023-08-07T14:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-veteran-receives-fda-approved-qalsody-for-sod1-als-at-houston-va-medical-center 2023-08-07T14:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-pharma-announces-breakthrough-therapy-designation-pr-newswire 2023-08-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jacobio-pharma-announces-breakthrough-therapy-designation-pr-newswire 2023-08-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-avacincaptad-pegol-for-geographic-atrophy 2023-08-05T14:10:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-avacincaptad-pegol-for-geographic-atrophy 2023-08-05T14:10:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-an-oral-treatment-for-postpartum-depression-called-zuranolone 2023-08-05T11:08:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-an-oral-treatment-for-postpartum-depression-called-zuranolone 2023-08-05T11:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/ugn-102-may-be-an-effective-non-surgical-option-for-bladder-cancer-subtype 2023-08-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ugn-102-may-be-an-effective-non-surgical-option-for-bladder-cancer-subtype 2023-08-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-the-endothelin-a-receptor-in-iga-nephropathy-a-new-therapeutic-approach 2023-08-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeting-the-endothelin-a-receptor-in-iga-nephropathy-a-new-therapeutic-approach 2023-08-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cage-bio-announces-positive-topline-results-from-its-phase-2-study-on-tofacitinib-for-atopic-dermatitis 2023-08-03T14:46:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cage-bio-announces-positive-topline-results-from-its-phase-2-study-on-tofacitinib-for-atopic-dermatitis 2023-08-03T14:46:08+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-could-ease-symptoms-of-children-with-adhd-wales-online 2023-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-treatment-could-ease-symptoms-of-children-with-adhd-wales-online 2023-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/actuate-therapeutics-receives-fda-orphan-drug 2023-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actuate-therapeutics-receives-fda-orphan-drug 2023-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-biosciences-announces-fda-orphan-drug-designation-for-tyra-300-for 2023-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tyra-biosciences-announces-fda-orphan-drug-designation-for-tyra-300-for 2023-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/obexelimab-shows-promise-in-treating-igg4-related-disease 2023-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obexelimab-shows-promise-in-treating-igg4-related-disease 2023-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-cancer-detection-tool-shows-13-boost-in-prostate-cancer-diagnosis-expands-to-breast-cancer-screening-in-wales 2023-07-31T00:27:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-cancer-detection-tool-shows-13-boost-in-prostate-cancer-diagnosis-expands-to-breast-cancer-screening-in-wales 2023-07-31T00:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-hcc-treatment-the-role-of-tace-combined-with-targeted-and-immune-therapies 2023-07-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-hcc-treatment-the-role-of-tace-combined-with-targeted-and-immune-therapies 2023-07-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-long-covid-treatment-clinical-trials-from-nih-getting-underway-cbs-news 2023-07-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-long-covid-treatment-clinical-trials-from-nih-getting-underway-cbs-news 2023-07-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/artificial-intelligence-enhances-diagnostic-accuracy-in-capsule-endoscopy-for-small-bowel-bleeding 2023-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/artificial-intelligence-enhances-diagnostic-accuracy-in-capsule-endoscopy-for-small-bowel-bleeding 2023-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-provides-regulatory-update-on-galactosemia-program 2023-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/applied-therapeutics-provides-regulatory-update-on-galactosemia-program 2023-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/safety-and-efficacy-of-ak0529-in-respiratory-syncytial-virus-infected-infant-patients 2023-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-and-efficacy-of-ak0529-in-respiratory-syncytial-virus-infected-infant-patients 2023-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/samuraciclib-shows-promise-in-advanced-breast-cancer-patients-after-cdk4-6-inhibitor-failure 2023-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/samuraciclib-shows-promise-in-advanced-breast-cancer-patients-after-cdk4-6-inhibitor-failure 2023-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/update-on-rapamycin-clinical-trial-for-pc-treatment 2023-07-21T18:39:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/update-on-rapamycin-clinical-trial-for-pc-treatment 2023-07-21T18:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/digital-transformation-reshapes-pharma-industry-with-30b-investment-drive 2023-07-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-transformation-reshapes-pharma-industry-with-30b-investment-drive 2023-07-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-vabysmo-shows-sustained-vision-improvements-with-extended-treatment-intervals-in-retinal-vein-occlusion-studies 2023-07-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-vabysmo-shows-sustained-vision-improvements-with-extended-treatment-intervals-in-retinal-vein-occlusion-studies 2023-07-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lucas-was-facing-life-in-a-wheelchair-until-a-medical-trial-gave-his-parents-hope-abc-news 2023-07-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lucas-was-facing-life-in-a-wheelchair-until-a-medical-trial-gave-his-parents-hope-abc-news 2023-07-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mind-diet-may-not-be-brain-boosting-in-the-short-term-new-clinical-trial-shows-cnn 2023-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mind-diet-may-not-be-brain-boosting-in-the-short-term-new-clinical-trial-shows-cnn 2023-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/magic-mushrooms-could-help-women-deal-with-cancer-related-depression-world-news-sky-news 2023-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/magic-mushrooms-could-help-women-deal-with-cancer-related-depression-world-news-sky-news 2023-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-nda-for-rivoceranib-camrelizumab-in-unresectable-hcc 2023-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-nda-for-rivoceranib-camrelizumab-in-unresectable-hcc 2023-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-finds-alzheimers-drug-donanemab-can-modestly-slow-memory-decline-the-new-york-times 2023-07-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-study-finds-alzheimers-drug-donanemab-can-modestly-slow-memory-decline-the-new-york-times 2023-07-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-follow-up-data-reinforce-efficacy-of-pembrolizumab-based-combinations-in-advanced-renal-cell-carcinoma 2023-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-follow-up-data-reinforce-efficacy-of-pembrolizumab-based-combinations-in-advanced-renal-cell-carcinoma 2023-07-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/polyunsaturated-fats-and-als-disease-progression-cap-1002-improves-motor-function-in-dmd-lecanemab-granted-traditional-approval 2023-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/polyunsaturated-fats-and-als-disease-progression-cap-1002-improves-motor-function-in-dmd-lecanemab-granted-traditional-approval 2023-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/experts-forecast-major-shifts-in-lung-cancer-treatment-immunotherapy-and-precision-medicine-lead-the-way 2023-07-13T04:44:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-forecast-major-shifts-in-lung-cancer-treatment-immunotherapy-and-precision-medicine-lead-the-way 2023-07-13T04:44:53+00:00 weekly 0.7 https://trial.medpath.com/news/pirtobrutinib-shows-promising-efficacy-in-cll-sll-patients-after-btk-inhibitor-failure 2023-07-12T14:00:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pirtobrutinib-shows-promising-efficacy-in-cll-sll-patients-after-btk-inhibitor-failure 2023-07-12T14:00:22+00:00 weekly 0.7 https://trial.medpath.com/news/dfd-29-bests-competition-for-papulopustular-rosacea-in-adults-practicaldermatology 2023-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dfd-29-bests-competition-for-papulopustular-rosacea-in-adults-practicaldermatology 2023-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-u-s-patients-implanted-with-innovative-fire1-remote-heart 2023-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-u-s-patients-implanted-with-innovative-fire1-remote-heart 2023-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biophytis-receives-fda-authorization-for-first-ever-phase-3-sarcopenia-trial 2023-07-10T11:55:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biophytis-receives-fda-authorization-for-first-ever-phase-3-sarcopenia-trial 2023-07-10T11:55:48+00:00 weekly 0.7 https://trial.medpath.com/news/tango-therapeutics-initiates-phase-1-2-trial-of-tng462-for-mtap-deleted-solid-tumors 2023-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tango-therapeutics-initiates-phase-1-2-trial-of-tng462-for-mtap-deleted-solid-tumors 2023-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-widens-door-to-research-on-psychedelics-like-ketamine-lsd-for-treatment-of-ptsd-depression-los-angeles-times 2023-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-widens-door-to-research-on-psychedelics-like-ketamine-lsd-for-treatment-of-ptsd-depression-los-angeles-times 2023-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-cap-1002-continues-to-show-preservation-of-cardiac-function-in-open-label-extension-study-of-dmd 2023-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cell-therapy-cap-1002-continues-to-show-preservation-of-cardiac-function-in-open-label-extension-study-of-dmd 2023-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/digital-care-program-shows-comparable-effectiveness-to-in-person-physiotherapy-for-chronic-low-back-pain 2023-07-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-care-program-shows-comparable-effectiveness-to-in-person-physiotherapy-for-chronic-low-back-pain 2023-07-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sulopenem-etzadroxil-probenecid-drug-market-forecast-and-analysis-sulopenem-etzadroxil-probenecid-for-uncomplicated-urinary-tract-infection-market-size-analysis-and-competitive-landscape-by-delveinsight 2023-07-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sulopenem-etzadroxil-probenecid-drug-market-forecast-and-analysis-sulopenem-etzadroxil-probenecid-for-uncomplicated-urinary-tract-infection-market-size-analysis-and-competitive-landscape-by-delveinsight 2023-07-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/people-with-alzheimers-urged-to-follow-fiona-phillips-and-join-drug-trials-alzheimer-s-the-guardian 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/people-with-alzheimers-urged-to-follow-fiona-phillips-and-join-drug-trials-alzheimer-s-the-guardian 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-launches-three-new-trial-sites-for-hemoperfusion-device-trial 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-launches-three-new-trial-sites-for-hemoperfusion-device-trial 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-achieves-milestone-with-1000th-alfapump-implant-advances-to-heart-failure-trial 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-achieves-milestone-with-1000th-alfapump-implant-advances-to-heart-failure-trial 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-to-know-about-leqembi-the-alzheimers-drug-approved-by-the-fda-the-new-york-times 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-to-know-about-leqembi-the-alzheimers-drug-approved-by-the-fda-the-new-york-times 2023-07-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-announces-publication-of-claudin18-2-x-4-1bb-biospace 2023-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-mab-announces-publication-of-claudin18-2-x-4-1bb-biospace 2023-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/margetuximab-an-active-alternative-for-later-line-therapy-in 2023-07-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/margetuximab-an-active-alternative-for-later-line-therapy-in 2023-07-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-dct-draft-guidance-a-hit-or-miss 2023-07-03T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-dct-draft-guidance-a-hit-or-miss 2023-07-03T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-fully-ai-generated-drug-enters-phase-ii-clinical-trials-for-idiopathic-pulmonary-fibrosis 2023-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-fully-ai-generated-drug-enters-phase-ii-clinical-trials-for-idiopathic-pulmonary-fibrosis 2023-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evaluation-of-the-one-step-nucleic-acid-amplification-method-for-rapid-detection-of-lymph-node-metastases-in-endometrial-cancer 2023-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluation-of-the-one-step-nucleic-acid-amplification-method-for-rapid-detection-of-lymph-node-metastases-in-endometrial-cancer 2023-07-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-approved-for-duchenne-muscular-dystrophy 2023-06-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-approved-for-duchenne-muscular-dystrophy 2023-06-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stock-roundup-srpt-s-dmd-therapy-approval-icpt-s-setback-more-updates 2023-06-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-stock-roundup-srpt-s-dmd-therapy-approval-icpt-s-setback-more-updates 2023-06-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hvivo-plc-develops-hmpv-human-challenge-model 2023-06-28T07:15:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hvivo-plc-develops-hmpv-human-challenge-model 2023-06-28T07:15:30+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-atogepant-shows-significant-efficacy-in-treatment-resistant-episodic-migraine-patients 2023-06-26T15:19:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-atogepant-shows-significant-efficacy-in-treatment-resistant-episodic-migraine-patients 2023-06-26T15:19:13+00:00 weekly 0.7 https://trial.medpath.com/news/janssen-submits-marketing-authorisation-application-to-the 2023-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/janssen-submits-marketing-authorisation-application-to-the 2023-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stock-market-financialcontent-business-page 2023-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stock-market-financialcontent-business-page 2023-06-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/approved-anti-obesity-medications-in-2022-a-comprehensive-overview 2023-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/approved-anti-obesity-medications-in-2022-a-comprehensive-overview 2023-06-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-submits-fda-application-for-updated-covid-19-vaccine-targeting-xbb-variants 2023-06-22T21:25:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-submits-fda-application-for-updated-covid-19-vaccine-targeting-xbb-variants 2023-06-22T21:25:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-cancer-drug-ruxolitinib-shows-promise-for-treating-cardiac-arrhythmias 2023-06-22T17:43:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approved-cancer-drug-ruxolitinib-shows-promise-for-treating-cardiac-arrhythmias 2023-06-22T17:43:12+00:00 weekly 0.7 https://trial.medpath.com/news/zanubrutinib-plus-obinutuzumab-and-venetoclax-shows-high-undetectable-mrd-rate-in-cll-sll 2023-06-22T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zanubrutinib-plus-obinutuzumab-and-venetoclax-shows-high-undetectable-mrd-rate-in-cll-sll 2023-06-22T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/navigating-complex-validation-challenges-in-atmp-analytical-methods-key-considerations-for-drug-development 2023-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/navigating-complex-validation-challenges-in-atmp-analytical-methods-key-considerations-for-drug-development 2023-06-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-positive-outcomes-from-north-american-pivotal-alfapump-study-poseidon 2023-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-announces-positive-outcomes-from-north-american-pivotal-alfapump-study-poseidon 2023-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-role-of-glp-1-agonists-in-obesity 2023-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emerging-role-of-glp-1-agonists-in-obesity 2023-06-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/anbalcabtagene-autoleucel-shows-84-response-rate-in-relapsed-refractory-large-b-cell-lymphoma 2023-06-20T20:26:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anbalcabtagene-autoleucel-shows-84-response-rate-in-relapsed-refractory-large-b-cell-lymphoma 2023-06-20T20:26:53+00:00 weekly 0.7 https://trial.medpath.com/news/tiny-implant-has-been-proven-to-half-the-number-of-hospital-admissions-for-heart-failure-daily-mail-online 2023-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiny-implant-has-been-proven-to-half-the-number-of-hospital-admissions-for-heart-failure-daily-mail-online 2023-06-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-delays-decision-on-gsk-bone-cancer-drug-acquired-in-2b-buyout 2023-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-delays-decision-on-gsk-bone-cancer-drug-acquired-in-2b-buyout 2023-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-avita-medical-s-recell-system-for-vitiligo-skin-repigmentation 2023-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-avita-medical-s-recell-system-for-vitiligo-skin-repigmentation 2023-06-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-ag-resminostat-marketing-application-proceeding-kinselby 2023-06-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4sc-ag-resminostat-marketing-application-proceeding-kinselby 2023-06-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/olix-pharmaceuticals-initiates-phase-i-trial-for-androgenic-alopecia-treatment 2023-06-14T10:47:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olix-pharmaceuticals-initiates-phase-i-trial-for-androgenic-alopecia-treatment 2023-06-14T10:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/immix-biopharma-completes-5-million-at-the-market-equity-offering-program 2023-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immix-biopharma-completes-5-million-at-the-market-equity-offering-program 2023-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/video-real-world-data-show-good-results-of-faricimab-in-dme-healio 2023-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/video-real-world-data-show-good-results-of-faricimab-in-dme-healio 2023-06-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/astellas-faces-setback-as-us-court-invalidates-key-myrbetriq-patent 2023-06-12T03:56:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astellas-faces-setback-as-us-court-invalidates-key-myrbetriq-patent 2023-06-12T03:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-durvalumab-plus-chemotherapy-reduces-disease-progression-risk-by-32-in-resectable-nsclc 2023-06-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perioperative-durvalumab-plus-chemotherapy-reduces-disease-progression-risk-by-32-in-resectable-nsclc 2023-06-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innovation-in-radionuclide-therapy-for-the-treatment 2023-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovation-in-radionuclide-therapy-for-the-treatment 2023-06-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/selinexor-shows-significant-survival-benefits-in-multiple-myeloma-subgroups-from-boston-trial 2023-06-09T16:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/selinexor-shows-significant-survival-benefits-in-multiple-myeloma-subgroups-from-boston-trial 2023-06-09T16:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-gene-therapies-show-promise-in-early-sickle-cell-disease-trials 2023-06-09T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crispr-gene-therapies-show-promise-in-early-sickle-cell-disease-trials 2023-06-09T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisers-vote-in-favor-of-infant-rsv-drug-time 2023-06-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-advisers-vote-in-favor-of-infant-rsv-drug-time 2023-06-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-revolutionizes-clinical-trials-three-key-innovations-transforming-patient-recruitment-and-retention 2023-06-07T23:19:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-revolutionizes-clinical-trials-three-key-innovations-transforming-patient-recruitment-and-retention 2023-06-07T23:19:13+00:00 weekly 0.7 https://trial.medpath.com/news/brainchild-04-study-is-enrolling-patients-with-brain-and-spinal-cord 2023-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brainchild-04-study-is-enrolling-patients-with-brain-and-spinal-cord 2023-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/frontiers-comparative-evaluation-of-clinical-glycemic-control-markers 2023-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frontiers-comparative-evaluation-of-clinical-glycemic-control-markers 2023-06-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-launches-constitutional-challenge-against-medicare-drug-price-negotiations 2023-06-06T09:56:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-launches-constitutional-challenge-against-medicare-drug-price-negotiations 2023-06-06T09:56:26+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-atr-inhibitor-camonsertib-shows-promise-in-dna-repair-deficient-cancers 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-atr-inhibitor-camonsertib-shows-promise-in-dna-repair-deficient-cancers 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uromems-achieves-breakthrough-with-first-smart-artificial-urinary-sphincter-implant-in-female-patient 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uromems-achieves-breakthrough-with-first-smart-artificial-urinary-sphincter-implant-in-female-patient 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-prioritizes-gsk-s-breakthrough-drug-jemperli-for-endometrial-cancer-treatment-a-first-in-decades 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-prioritizes-gsk-s-breakthrough-drug-jemperli-for-endometrial-cancer-treatment-a-first-in-decades 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-subpopulation-analysis-of-the-phase-3-arasens-study 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-subpopulation-analysis-of-the-phase-3-arasens-study 2023-06-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sensydia-secures-3m-nih-grant-to-advance-ai-based-cardiac-assessment-platform-biospace 2023-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sensydia-secures-3m-nih-grant-to-advance-ai-based-cardiac-assessment-platform-biospace 2023-06-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/avutometinib-defactinib-combination-shows-45-response-rate-in-low-grade-serous-ovarian-cancer 2023-06-04T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avutometinib-defactinib-combination-shows-45-response-rate-in-low-grade-serous-ovarian-cancer 2023-06-04T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vorasidenib-shows-promise-as-first-targeted-therapy-for-idh-mutant-low-grade-gliomas 2023-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vorasidenib-shows-promise-as-first-targeted-therapy-for-idh-mutant-low-grade-gliomas 2023-06-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-to-present-new-oncology-data-at-asco-2023 2023-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-to-present-new-oncology-data-at-asco-2023 2023-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-tuberous-sclerosis-drug-market-projected-to-reach-1-25-billion-by-2030-growing-at-23-1-cagr 2023-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-tuberous-sclerosis-drug-market-projected-to-reach-1-25-billion-by-2030-growing-at-23-1-cagr 2023-06-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/varmx-secures-eur30m-series-b2-funding-to-advance-anticoagulation-reversal-drug-vmx-c001-toward-pivotal-trial 2023-06-01T09:35:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/varmx-secures-eur30m-series-b2-funding-to-advance-anticoagulation-reversal-drug-vmx-c001-toward-pivotal-trial 2023-06-01T09:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/nfl-biosciences-nfl-101-shows-promise-as-first-in-class-smoking-cessation-treatment-in-phase-2-trial 2023-06-01T08:00:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nfl-biosciences-nfl-101-shows-promise-as-first-in-class-smoking-cessation-treatment-in-phase-2-trial 2023-06-01T08:00:14+00:00 weekly 0.7 https://trial.medpath.com/news/avacta-acquires-belgium-based-coris-bioconcept-for-ps7-4-million-to-expand-diagnostics-portfolio 2023-06-01T05:59:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avacta-acquires-belgium-based-coris-bioconcept-for-ps7-4-million-to-expand-diagnostics-portfolio 2023-06-01T05:59:44+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-in-essential-thrombocythemia-et 2023-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-in-essential-thrombocythemia-et 2023-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1-2a-clinical-trial-in-als-with-ropinirole-a-drug 2023-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-1-2a-clinical-trial-in-als-with-ropinirole-a-drug 2023-06-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/metriopharm-s-mp1032-receives-fda-orphan-drug-designation-for-duchenne-muscular-dystrophy-treatment 2023-05-30T09:06:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/metriopharm-s-mp1032-receives-fda-orphan-drug-designation-for-duchenne-muscular-dystrophy-treatment 2023-05-30T09:06:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-psma-targeted-pet-imaging-agent-for-prostate-cancer 2023-05-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-psma-targeted-pet-imaging-agent-for-prostate-cancer 2023-05-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sunlight-and-fresco-2-trials-show-promising-results-for-refractory-colorectal-cancer-treatment 2023-05-29T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sunlight-and-fresco-2-trials-show-promising-results-for-refractory-colorectal-cancer-treatment 2023-05-29T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/update-on-the-efficacy-of-venetoclax-for-chronic-lymphocytic-leukemia 2023-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/update-on-the-efficacy-of-venetoclax-for-chronic-lymphocytic-leukemia 2023-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-trial-explores-ribociclib-plus-endocrine-therapy-for-early-breast-cancer 2023-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-trial-explores-ribociclib-plus-endocrine-therapy-for-early-breast-cancer 2023-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-reports-data-from-phase-ib-ii-nsclc-combo-therapy-trial 2023-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-mab-reports-data-from-phase-ib-ii-nsclc-combo-therapy-trial 2023-05-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/usda-approves-first-therapeutic-treatment-for-canine-parvovirus-using-monoclonal-antibody-technology 2023-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/usda-approves-first-therapeutic-treatment-for-canine-parvovirus-using-monoclonal-antibody-technology 2023-05-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musks-brain-implant-technology-gains-fda-approval-fox-business 2023-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musks-brain-implant-technology-gains-fda-approval-fox-business 2023-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-gene-therapy-for-rare-skin-disease-but-costs-are-outrageous-cbs-colorado 2023-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-gene-therapy-for-rare-skin-disease-but-costs-are-outrageous-cbs-colorado 2023-05-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tvardi-therapeutics-to-present-phase-1-trial-data-of-stat3-inhibitor-tti-101-at-asco-2023 2023-05-25T09:51:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tvardi-therapeutics-to-present-phase-1-trial-data-of-stat3-inhibitor-tti-101-at-asco-2023 2023-05-25T09:51:08+00:00 weekly 0.7 https://trial.medpath.com/news/bial-r-d-announces-first-patient-dosed-in-its-phase-2-clinical-trial-of 2023-05-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bial-r-d-announces-first-patient-dosed-in-its-phase-2-clinical-trial-of 2023-05-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vega-therapeutics-receives-fda-orphan-drug 2023-05-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vega-therapeutics-receives-fda-orphan-drug 2023-05-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/valbiotis-announces-success-of-reverse-it-clinical-study-on-totum-63 2023-05-22T17:40:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valbiotis-announces-success-of-reverse-it-clinical-study-on-totum-63 2023-05-22T17:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/microbiome-modulation-with-sim01-shows-promise-for-long-covid-treatment-in-randomized-trial 2023-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/microbiome-modulation-with-sim01-shows-promise-for-long-covid-treatment-in-randomized-trial 2023-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-highlights-delays-in-confirmatory-studies-for-accelerated-fda-approvals 2023-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-highlights-delays-in-confirmatory-studies-for-accelerated-fda-approvals 2023-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/heart-device-breakthrough-next-cochlear-stock-ebr-systems-surges-after-heart-device-breakthrough-surges-after-heart-device-breakthrough 2023-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heart-device-breakthrough-next-cochlear-stock-ebr-systems-surges-after-heart-device-breakthrough-surges-after-heart-device-breakthrough 2023-05-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nexcella-announces-positive-nxc-201-clinical-results-at-asgct-100-overall-response-rate-in-darzalex-relapsed-refractory-al-amyloidosis-with-zero-icans-in-ongoing-nexicart-1-phase-1b-2a-clinical-trial-biospace 2023-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nexcella-announces-positive-nxc-201-clinical-results-at-asgct-100-overall-response-rate-in-darzalex-relapsed-refractory-al-amyloidosis-with-zero-icans-in-ongoing-nexicart-1-phase-1b-2a-clinical-trial-biospace 2023-05-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-two-bispecific-t-cell-engagers-for-relapsed-refractory-b-cell-lymphomas 2023-05-19T17:12:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-two-bispecific-t-cell-engagers-for-relapsed-refractory-b-cell-lymphomas 2023-05-19T17:12:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-approves-krystal-biotech-s-skin-disorder-gene-therapy 2023-05-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-approves-krystal-biotech-s-skin-disorder-gene-therapy 2023-05-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-clinical-trial-matching-platforms-show-promise-in-addressing-patient-recruitment-challenges 2023-05-18T02:04:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-powered-clinical-trial-matching-platforms-show-promise-in-addressing-patient-recruitment-challenges 2023-05-18T02:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/satsuma-pharmaceuticals-announces-fda-acceptance-of-505-b-2-nda-for 2023-05-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/satsuma-pharmaceuticals-announces-fda-acceptance-of-505-b-2-nda-for 2023-05-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/siren-biotechnology-unveils-promising-preclinical-data-for-novel-cancer-treatment-combining-aav-gene-therapy-with-cytokine-immunotherapy 2023-05-17T00:01:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/siren-biotechnology-unveils-promising-preclinical-data-for-novel-cancer-treatment-combining-aav-gene-therapy-with-cytokine-immunotherapy 2023-05-17T00:01:02+00:00 weekly 0.7 https://trial.medpath.com/news/elevar-therapeutics-submits-new-drug-application-to-fda-for-combination 2023-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elevar-therapeutics-submits-new-drug-application-to-fda-for-combination 2023-05-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aging-dogs-provide-insights-for-human-longevity 2023-05-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aging-dogs-provide-insights-for-human-longevity 2023-05-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biophytis-receives-regulatory-approval-to-launch-first-ever-phase-3-trial-for-sarcopenia-treatment 2023-05-15T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biophytis-receives-regulatory-approval-to-launch-first-ever-phase-3-trial-for-sarcopenia-treatment 2023-05-15T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/local-news-tailored-for-you-citybiz 2023-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/local-news-tailored-for-you-citybiz 2023-05-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tucatinib-plus-trastuzumab-shows-promise-for-her2-positive-metastatic-colorectal-cancer 2023-05-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tucatinib-plus-trastuzumab-shows-promise-for-her2-positive-metastatic-colorectal-cancer 2023-05-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/skin-patch-developed-with-ucc-researchers-helps-ease-peanut-allergy-symptoms-in-toddlers-the-irish-times 2023-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/skin-patch-developed-with-ucc-researchers-helps-ease-peanut-allergy-symptoms-in-toddlers-the-irish-times 2023-05-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/skyrocketing-popularity-puts-glp-1-agonists-for-weight-loss-on-cardiologys-radar 2023-05-12T17:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/skyrocketing-popularity-puts-glp-1-agonists-for-weight-loss-on-cardiologys-radar 2023-05-12T17:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/novo-holdings-leads-200m-series-a-investment-in-windward-bio-for-advanced-respiratory-treatments 2023-05-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-holdings-leads-200m-series-a-investment-in-windward-bio-for-advanced-respiratory-treatments 2023-05-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kintor-pharma-s-kx-826-shows-statistically-significant-hair-growth-in-us-phase-ii-trial-for-male-pattern-baldness 2023-05-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kintor-pharma-s-kx-826-shows-statistically-significant-hair-growth-in-us-phase-ii-trial-for-male-pattern-baldness 2023-05-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mirocals-trial-results-low-dose-il-2-shows-potential-benefit-for-subset-of-mnd-patients 2023-05-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mirocals-trial-results-low-dose-il-2-shows-potential-benefit-for-subset-of-mnd-patients 2023-05-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-atezolizumab-and-bevacizumab-delays-recurrence-in-early-stage-hcc 2023-05-10T19:03:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adjuvant-atezolizumab-and-bevacizumab-delays-recurrence-in-early-stage-hcc 2023-05-10T19:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-guidance-agenda-what-is-cder-cooking-for-clinical-trials 2023-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-guidance-agenda-what-is-cder-cooking-for-clinical-trials 2023-05-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/paradigm-trial-highlights-egfr-targeting-therapy-benefits-for-metastatic-colorectal-cancer 2023-05-08T12:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paradigm-trial-highlights-egfr-targeting-therapy-benefits-for-metastatic-colorectal-cancer 2023-05-08T12:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/lorlatinib-shows-promise-in-alk-driven-refractory-neuroblastoma-with-emerging-resistance-mechanisms-identified 2023-05-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lorlatinib-shows-promise-in-alk-driven-refractory-neuroblastoma-with-emerging-resistance-mechanisms-identified 2023-05-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-safety-and-efficacy-of-mesenchymal-stem-cell-therapy-in-severe-covid-19-patients 2023-05-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-safety-and-efficacy-of-mesenchymal-stem-cell-therapy-in-severe-covid-19-patients 2023-05-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthroughs-in-biotech-promising-developments-in-diabetes-cancer-and-lymphoma-treatments 2023-05-04T17:56:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthroughs-in-biotech-promising-developments-in-diabetes-cancer-and-lymphoma-treatments 2023-05-04T17:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/visus-therapeutics-announces-positive-phase-3-clinical-trial-results-for-brimocholtm-pf-in-treating-presbyopia 2023-05-04T12:16:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/visus-therapeutics-announces-positive-phase-3-clinical-trial-results-for-brimocholtm-pf-in-treating-presbyopia 2023-05-04T12:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/an-rsv-vaccine-has-been-approved-by-the-fda-its-a-huge-deal-vox 2023-05-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-rsv-vaccine-has-been-approved-by-the-fda-its-a-huge-deal-vox 2023-05-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-trial-finds-alzheimers-drug-can-slow-progress-of-disease-the-new-york-times 2023-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-trial-finds-alzheimers-drug-can-slow-progress-of-disease-the-new-york-times 2023-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaessentia-initiates-phase-3b-trial-of 2023-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmaessentia-initiates-phase-3b-trial-of 2023-05-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-expands-cell-therapy-portfolio-with-new-car-t-deals 2023-05-02T12:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-expands-cell-therapy-portfolio-with-new-car-t-deals 2023-05-02T12:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-in-early-alzheimer-s-disease 2023-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lecanemab-in-early-alzheimer-s-disease 2023-05-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/experimental-brain-cancer-vaccine-survaxm-shows-promise-in-extending-glioblastoma-survival-to-26-months 2023-04-30T19:50:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experimental-brain-cancer-vaccine-survaxm-shows-promise-in-extending-glioblastoma-survival-to-26-months 2023-04-30T19:50:49+00:00 weekly 0.7 https://trial.medpath.com/news/church-based-intervention-aims-to-reduce-blood-pressure-in-african-americans 2023-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/church-based-intervention-aims-to-reduce-blood-pressure-in-african-americans 2023-04-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/toripalimab-combo-shows-superior-survival-over-sunitinib-in-renal-cell-carcinoma 2023-04-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/toripalimab-combo-shows-superior-survival-over-sunitinib-in-renal-cell-carcinoma 2023-04-28T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iomt-set-to-transform-healthcare-with-486b-market-projection-by-2031 2023-04-28T02:23:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iomt-set-to-transform-healthcare-with-486b-market-projection-by-2031 2023-04-28T02:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-recommends-extension-of-indications-for-nivolumab 2023-04-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-recommends-extension-of-indications-for-nivolumab 2023-04-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-tirzepatide-shows-superior-weight-loss-results-in-diabetes-patients-fda-approval-expected-by-year-end 2023-04-27T21:58:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-s-tirzepatide-shows-superior-weight-loss-results-in-diabetes-patients-fda-approval-expected-by-year-end 2023-04-27T21:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/novel-bcma-targeted-therapies-and-emerging-agents-transform-treatment-landscape-for-relapsed-refractory-multiple-myeloma 2023-04-26T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-bcma-targeted-therapies-and-emerging-agents-transform-treatment-landscape-for-relapsed-refractory-multiple-myeloma 2023-04-26T18:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-unveils-ambitious-pharmaceutical-reform-single-market-plan-sparks-industry-debate 2023-04-26T06:02:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-unveils-ambitious-pharmaceutical-reform-single-market-plan-sparks-industry-debate 2023-04-26T06:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study 2023-04-26T05:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alentis-therapeutics-reports-positive-topline-results-from-phase-1-multiple-ascending-dose-cohorts-study 2023-04-26T05:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/dual-action-hydrogel-prevents-brain-cancer-returning-in-100-of-test-mice 2023-04-26T03:26:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dual-action-hydrogel-prevents-brain-cancer-returning-in-100-of-test-mice 2023-04-26T03:26:09+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-receives-fda-approval-for-breakthrough-als-treatment-pivotal-moment-in-als-research 2023-04-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-receives-fda-approval-for-breakthrough-als-treatment-pivotal-moment-in-als-research 2023-04-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/one-week-elderberry-juice-treatment-increases-postprandial-carbohydrate-oxidation 2023-04-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/one-week-elderberry-juice-treatment-increases-postprandial-carbohydrate-oxidation 2023-04-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-for-psma-positive-metastatic-castration-resistant-prostate-cancer 2023-04-24T20:00:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-for-psma-positive-metastatic-castration-resistant-prostate-cancer 2023-04-24T20:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/leaked-data-show-cilta-cel-delivers-74-reduction-in-risk-of 2023-04-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leaked-data-show-cilta-cel-delivers-74-reduction-in-risk-of 2023-04-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelics-may-better-treat-depression-and-anxiety-symptoms-than 2023-04-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psychedelics-may-better-treat-depression-and-anxiety-symptoms-than 2023-04-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sleeping-pill-shows-potential-in-reducing-alzheimer-s-proteins 2023-04-20T14:00:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sleeping-pill-shows-potential-in-reducing-alzheimer-s-proteins 2023-04-20T14:00:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-botensilimab-plus-balstilimab-for-non-msi-h-dmmr-metastatic-colorectal-cancer 2023-04-20T13:00:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-botensilimab-plus-balstilimab-for-non-msi-h-dmmr-metastatic-colorectal-cancer 2023-04-20T13:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-withdraws-authorization-for-original-covid-19-vaccines 2023-04-19T18:11:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-withdraws-authorization-for-original-covid-19-vaccines 2023-04-19T18:11:34+00:00 weekly 0.7 https://trial.medpath.com/news/second-omicron-booster-authorized 2023-04-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/second-omicron-booster-authorized 2023-04-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-omidubicel-for-blood-cancers-in-need-of-transplant 2023-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-omidubicel-for-blood-cancers-in-need-of-transplant 2023-04-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/insilico-medicine-leverages-ai-to-develop-novel-cdk8-inhibitor-for-cancer-treatment 2023-04-13T00:13:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insilico-medicine-leverages-ai-to-develop-novel-cdk8-inhibitor-for-cancer-treatment 2023-04-13T00:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/naxswabtm-otc-novel-naloxone-nasal-swab-successfully-administered-by-children-and-adults-to-potentially-rescue-someone-from-an-opioid-overdose-in-study 2023-04-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/naxswabtm-otc-novel-naloxone-nasal-swab-successfully-administered-by-children-and-adults-to-potentially-rescue-someone-from-an-opioid-overdose-in-study 2023-04-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/revumenib-shows-breakthrough-results-in-advanced-acute-myeloid-leukemia-trial 2023-04-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revumenib-shows-breakthrough-results-in-advanced-acute-myeloid-leukemia-trial 2023-04-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/almirall-launches-first-dermatology-study-to-assess-patient-wellbeing-as-primary-endpoint-in-psoriasis-treatment 2023-04-12T11:21:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/almirall-launches-first-dermatology-study-to-assess-patient-wellbeing-as-primary-endpoint-in-psoriasis-treatment 2023-04-12T11:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/alebund-pharmaceuticals-secures-nearly-rmb-200-million-in-pre-c-round-financing 2023-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alebund-pharmaceuticals-secures-nearly-rmb-200-million-in-pre-c-round-financing 2023-04-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-plus-lenvatinib-fails-to-meet-primary-endpoints-in-melanoma-and-colorectal-cancer-trials 2023-04-07T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-plus-lenvatinib-fails-to-meet-primary-endpoints-in-melanoma-and-colorectal-cancer-trials 2023-04-07T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-awards-prime-scheme-designation-to-mrna-4157 2023-04-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-awards-prime-scheme-designation-to-mrna-4157 2023-04-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acalabrutinib-avo-triplet-therapy-in-high-risk-cll 2023-04-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acalabrutinib-avo-triplet-therapy-in-high-risk-cll 2023-04-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-emergency-use-authorization-for-vilobelimab-in-treating-critically-ill-covid-19-patients 2023-04-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-emergency-use-authorization-for-vilobelimab-in-treating-critically-ill-covid-19-patients 2023-04-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nexcella-announces-2023-haematologica-editorial-highlighting-nxc-201-efficacy-in-the-context-of-u-s-food-and-drug-administration-approved-bcma-car-t-cells-nexcella-inc 2023-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nexcella-announces-2023-haematologica-editorial-highlighting-nxc-201-efficacy-in-the-context-of-u-s-food-and-drug-administration-approved-bcma-car-t-cells-nexcella-inc 2023-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-provides-business-and-corporate-updates-and 2023-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-mab-provides-business-and-corporate-updates-and 2023-03-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/generic-manufacturers-secure-licenses-for-long-acting-hiv-prevention-drug-cabotegravir 2023-03-30T09:24:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/generic-manufacturers-secure-licenses-for-long-acting-hiv-prevention-drug-cabotegravir 2023-03-30T09:24:25+00:00 weekly 0.7 https://trial.medpath.com/news/tracking-the-covid-19-vaccines-the-global-landscape 2023-03-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tracking-the-covid-19-vaccines-the-global-landscape 2023-03-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/atezolizumab-enhances-immunogenicity-in-cervical-cancer-treatment 2023-03-29T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atezolizumab-enhances-immunogenicity-in-cervical-cancer-treatment 2023-03-29T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/who-panel-to-review-obesity-drug-liraglutide-for-essential-medicines-list 2023-03-29T14:22:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-panel-to-review-obesity-drug-liraglutide-for-essential-medicines-list 2023-03-29T14:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/nih-releases-data-showing-more-clinical-trial-sponsors-are-reporting-results-but-most-miss-deadlines 2023-03-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-releases-data-showing-more-clinical-trial-sponsors-are-reporting-results-but-most-miss-deadlines 2023-03-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-guidelines-to-support-applications-for-accelerated-approvals 2023-03-28T19:00:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-guidelines-to-support-applications-for-accelerated-approvals 2023-03-28T19:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/thermosome-s-the001-receives-regulatory-approval-for-first-in-human-trial-in-soft-tissue-sarcoma 2023-03-28T08:00:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thermosome-s-the001-receives-regulatory-approval-for-first-in-human-trial-in-soft-tissue-sarcoma 2023-03-28T08:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/radiopharm-theranostics-expands-partnership-with-genesiscare-for-phase-i-radiopharmaceutical-trials-in-australia 2023-03-27T15:09:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiopharm-theranostics-expands-partnership-with-genesiscare-for-phase-i-radiopharmaceutical-trials-in-australia 2023-03-27T15:09:34+00:00 weekly 0.7 https://trial.medpath.com/news/kala-pharmaceuticals-provides-safety-update-and-completes-enrollment-for-chase-phase-2b-trial 2023-03-27T12:04:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kala-pharmaceuticals-provides-safety-update-and-completes-enrollment-for-chase-phase-2b-trial 2023-03-27T12:04:03+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-pembrolizumab-improves-event-free-survival-in-advanced-melanoma-patients 2023-03-23T14:09:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-pembrolizumab-improves-event-free-survival-in-advanced-melanoma-patients 2023-03-23T14:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/olix-pharmaceuticals-receives-approval-for-phase-1-clinical-trial-of-new-hair-loss-treatment 2023-03-23T11:06:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olix-pharmaceuticals-receives-approval-for-phase-1-clinical-trial-of-new-hair-loss-treatment 2023-03-23T11:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/asciminib-monotherapy-in-patients-with-cml-cp-without-bcr-abl1-t315i-mutations-treated-with-at-least-two-prior-tkis-4-year-phase-1-safety-and-efficacy-results-leukemia 2023-03-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asciminib-monotherapy-in-patients-with-cml-cp-without-bcr-abl1-t315i-mutations-treated-with-at-least-two-prior-tkis-4-year-phase-1-safety-and-efficacy-results-leukemia 2023-03-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-introduces-new-measures-to-streamline-clinical-trial-approvals-in-the-uk 2023-03-21T12:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mhra-introduces-new-measures-to-streamline-clinical-trial-approvals-in-the-uk 2023-03-21T12:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-technology-revolutionizes-rare-disease-diagnosis-reducing-detection-time-by-4-4-years 2023-03-20T02:18:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-technology-revolutionizes-rare-disease-diagnosis-reducing-detection-time-by-4-4-years 2023-03-20T02:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/nubeqatm-darolutamide-approved-for-additional-prostate 2023-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nubeqatm-darolutamide-approved-for-additional-prostate 2023-03-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/toripalimab-combined-with-lenvatinib-and-gemox-is-a 2023-03-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/toripalimab-combined-with-lenvatinib-and-gemox-is-a 2023-03-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bispecific-cd20-cd19-car-t-cell-therapy-shows-promising-results-in-mantle-cell-lymphoma 2023-03-16T15:00:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bispecific-cd20-cd19-car-t-cell-therapy-shows-promising-results-in-mantle-cell-lymphoma 2023-03-16T15:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-reinstated-to-abpi-after-two-year-suspension-for-code-violations 2023-03-16T03:16:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-reinstated-to-abpi-after-two-year-suspension-for-code-violations 2023-03-16T03:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/revumenib-shows-promise-in-phase-1-trial-for-kmt2a-rearranged-and-npm1-mutated-acute-leukemia 2023-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revumenib-shows-promise-in-phase-1-trial-for-kmt2a-rearranged-and-npm1-mutated-acute-leukemia 2023-03-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sapience-therapeutics-receives-ind-clearance-from-fda-to-proceed-with 2023-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sapience-therapeutics-receives-ind-clearance-from-fda-to-proceed-with 2023-03-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/israeli-scientists-develop-world-s-first-mrna-vaccine-against-antibiotic-resistant-bacteria 2023-03-12T07:04:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/israeli-scientists-develop-world-s-first-mrna-vaccine-against-antibiotic-resistant-bacteria 2023-03-12T07:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/quanterix-launches-novel-p-tau-205-and-p-tau-212-assays-to-advance-alzheimer-s-research 2023-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quanterix-launches-novel-p-tau-205-and-p-tau-212-assays-to-advance-alzheimer-s-research 2023-03-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/digital-health-measures-transform-patient-care-through-pre-competitive-industry-collaboration 2023-03-10T04:20:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-health-measures-transform-patient-care-through-pre-competitive-industry-collaboration 2023-03-10T04:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/palvella-therapeutics-announces-positive-topline-results-from-phase-2-study-for-microcystic-lymphatic-malformations 2023-03-09T14:24:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palvella-therapeutics-announces-positive-topline-results-from-phase-2-study-for-microcystic-lymphatic-malformations 2023-03-09T14:24:54+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-concludes-solanezumab-development-after-alzheimer-s-study-fails 2023-03-09T12:35:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-concludes-solanezumab-development-after-alzheimer-s-study-fails 2023-03-09T12:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/invox-pharma-completes-161-million-acquisition-of-f-star-therapeutics-to-strengthen-bispecific-antibody-pipeline 2023-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invox-pharma-completes-161-million-acquisition-of-f-star-therapeutics-to-strengthen-bispecific-antibody-pipeline 2023-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/therapeutic-trials-for-long-covid-19-a-call-to-action 2023-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/therapeutic-trials-for-long-covid-19-a-call-to-action 2023-03-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/randomized-clinical-trial-of-neoadjuvant-therapy-for-escc-shows-promising-results 2023-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/randomized-clinical-trial-of-neoadjuvant-therapy-for-escc-shows-promising-results 2023-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tailored-axillary-surgery-a-novel-approach-for-clinically-node-positive-breast-cancer 2023-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tailored-axillary-surgery-a-novel-approach-for-clinically-node-positive-breast-cancer 2023-03-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-and-msd-s-mrna-cancer-vaccine-shows-44-reduction-in-melanoma-recurrence-risk 2023-03-06T19:03:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-and-msd-s-mrna-cancer-vaccine-shows-44-reduction-in-melanoma-recurrence-risk 2023-03-06T19:03:37+00:00 weekly 0.7 https://trial.medpath.com/news/avo-triplet-regimen-continues-to-show-durable-responses-in-high-risk-cll 2023-03-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avo-triplet-regimen-continues-to-show-durable-responses-in-high-risk-cll 2023-03-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-sbla-for-traditional-approval-of-leqembi-for-alzheimer-s-disease-treatment 2023-03-05T23:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-sbla-for-traditional-approval-of-leqembi-for-alzheimer-s-disease-treatment 2023-03-05T23:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-to-establish-uk-innovation-and-technology-centre-at-harwell-science-campus-by-2025 2023-03-05T16:15:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-to-establish-uk-innovation-and-technology-centre-at-harwell-science-campus-by-2025 2023-03-05T16:15:49+00:00 weekly 0.7 https://trial.medpath.com/news/evolution-of-axillary-management-in-breast-cancer-therapy-a-focus-on-de-escalation-and-escalation-strategies 2023-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evolution-of-axillary-management-in-breast-cancer-therapy-a-focus-on-de-escalation-and-escalation-strategies 2023-03-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/trastuzumab-deruxtecan-gains-regulatory-approvals-in-china-and-europe-for-her2-positive-cancers 2023-03-02T17:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trastuzumab-deruxtecan-gains-regulatory-approvals-in-china-and-europe-for-her2-positive-cancers 2023-03-02T17:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/impacts-of-fda-approval-and-medicare-restriction 2023-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impacts-of-fda-approval-and-medicare-restriction 2023-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/omission-of-axillary-lymph-node-dissection-in-breast-cancer-patients-with-residual-nodal-disease-after-neoadjuvant-chemotherapy 2023-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omission-of-axillary-lymph-node-dissection-in-breast-cancer-patients-with-residual-nodal-disease-after-neoadjuvant-chemotherapy 2023-03-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1b-clinical-trial-results-for-socazolimab-in-es-sclc-treatment 2023-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-1b-clinical-trial-results-for-socazolimab-in-es-sclc-treatment 2023-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/canadian-founded-company-develops-first-ai-designed-covid-19-drug-starts-clinical-trials 2023-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/canadian-founded-company-develops-first-ai-designed-covid-19-drug-starts-clinical-trials 2023-02-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/avutometinib-plus-defactinib-generates-responses-in 2023-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avutometinib-plus-defactinib-generates-responses-in 2023-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ux111-shows-continued-dose-dependent-efficacy-as-an 2023-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ux111-shows-continued-dose-dependent-efficacy-as-an 2023-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/survival-outcomes-in-braf-v600e-mutated-advanced-colorectal-cancer-chemotherapy-alone-vs-chemotherapy-combined-with-bevacizumab 2023-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/survival-outcomes-in-braf-v600e-mutated-advanced-colorectal-cancer-chemotherapy-alone-vs-chemotherapy-combined-with-bevacizumab 2023-02-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/blue-lake-biotechnology-s-nasal-covid-19-vaccine-shows-86-efficacy-in-phase-1-trial 2023-02-24T20:26:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blue-lake-biotechnology-s-nasal-covid-19-vaccine-shows-86-efficacy-in-phase-1-trial 2023-02-24T20:26:43+00:00 weekly 0.7 https://trial.medpath.com/news/study-to-evaluate-expanded-methadone-access-amid-opioid-crisis 2023-02-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-to-evaluate-expanded-methadone-access-amid-opioid-crisis 2023-02-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-completes-1-3-billion-acquisition-of-cincor-pharma-for-hypertension-drug-baxdrostat 2023-02-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-completes-1-3-billion-acquisition-of-cincor-pharma-for-hypertension-drug-baxdrostat 2023-02-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/is-it-still-worth-pursuing-the-repurposing-of-metformin-as-a-cancer 2023-02-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-it-still-worth-pursuing-the-repurposing-of-metformin-as-a-cancer 2023-02-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/promius-pharma-advances-minocycline-hydrochloride-er-development-for-rosacea-treatment 2023-02-22T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promius-pharma-advances-minocycline-hydrochloride-er-development-for-rosacea-treatment 2023-02-22T15:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alteogen-s-subsidiary-completes-phase-iii-enrollment-for-eylea-biosimilar-in-wet-amd 2023-02-22T00:34:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alteogen-s-subsidiary-completes-phase-iii-enrollment-for-eylea-biosimilar-in-wet-amd 2023-02-22T00:34:10+00:00 weekly 0.7 https://trial.medpath.com/news/doxycycline-for-sti-prevention-highly-effective-minimal-drug 2023-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doxycycline-for-sti-prevention-highly-effective-minimal-drug 2023-02-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-industry-braces-for-200b-patent-cliff-as-biologics-face-biosimilar-competition 2023-02-20T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-industry-braces-for-200b-patent-cliff-as-biologics-face-biosimilar-competition 2023-02-20T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-belantamab-mafodotin-expands-development-portfolio-to-target-diffuse-large-b-cell-lymphoma 2023-02-20T08:21:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-s-belantamab-mafodotin-expands-development-portfolio-to-target-diffuse-large-b-cell-lymphoma 2023-02-20T08:21:08+00:00 weekly 0.7 https://trial.medpath.com/news/novel-gene-therapies-and-biomarkers-advance-the-fight-against-frontotemporal-dementia 2023-02-20T06:16:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-gene-therapies-and-biomarkers-advance-the-fight-against-frontotemporal-dementia 2023-02-20T06:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/pragmatica-lung-trial-pioneers-streamlined-approach-to-cancer-drug-development-in-advanced-nsclc 2023-02-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pragmatica-lung-trial-pioneers-streamlined-approach-to-cancer-drug-development-in-advanced-nsclc 2023-02-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bladder-sparing-risk-enabled-therapy-after-initiating 2023-02-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bladder-sparing-risk-enabled-therapy-after-initiating 2023-02-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lamzede-for-alpha-mannosidosis-treatment 2023-02-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lamzede-for-alpha-mannosidosis-treatment 2023-02-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-adcs-and-serds-transform-breast-cancer-treatment-landscape 2023-02-15T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/next-generation-adcs-and-serds-transform-breast-cancer-treatment-landscape 2023-02-15T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acr-initiatives-to-reduce-disparities-in-clinical-trials 2023-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acr-initiatives-to-reduce-disparities-in-clinical-trials 2023-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisers-to-consider-emergents-ebs-narcan-spray-as-otc-overdose-antidote-bloomberg 2023-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-advisers-to-consider-emergents-ebs-narcan-spray-as-otc-overdose-antidote-bloomberg 2023-02-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lg-chem-completes-571-million-aveo-acquisition-to-accelerate-us-cancer-market-entry 2023-02-14T10:49:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lg-chem-completes-571-million-aveo-acquisition-to-accelerate-us-cancer-market-entry 2023-02-14T10:49:01+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-significantly-improves-survival-rates-for-operable-bladder-cancer-patients 2023-02-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-significantly-improves-survival-rates-for-operable-bladder-cancer-patients 2023-02-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nci-selects-two-assays-for-vanguard-study-on-multi-cancer-detection-tests 2023-02-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nci-selects-two-assays-for-vanguard-study-on-multi-cancer-detection-tests 2023-02-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/seastar-medical-receives-fda-approval-to-begin-study 2023-02-09T13:19:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seastar-medical-receives-fda-approval-to-begin-study 2023-02-09T13:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/people-are-taking-a-20-cent-wonder-drug-to-slow-aging-and-lose-weight-some-doctors-say-it-s-promising 2023-02-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/people-are-taking-a-20-cent-wonder-drug-to-slow-aging-and-lose-weight-some-doctors-say-it-s-promising 2023-02-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-approaches-in-igan-treatment-the-applause-igan-study 2023-02-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-approaches-in-igan-treatment-the-applause-igan-study 2023-02-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-ezurpimtrostat-for-hcc-treatment 2023-02-08T18:58:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-ezurpimtrostat-for-hcc-treatment 2023-02-08T18:58:44+00:00 weekly 0.7 https://trial.medpath.com/news/neogap-receives-approval-for-clinical-trial-cision-news 2023-02-06T06:25:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neogap-receives-approval-for-clinical-trial-cision-news 2023-02-06T06:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-reaches-enrolment-target-for-insight-003-trial 2023-02-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-reaches-enrolment-target-for-insight-003-trial 2023-02-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/canadian-developed-car-t-cell-therapy-targeting-cd22-heads-to-clinical-trials 2023-02-03T10:02:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/canadian-developed-car-t-cell-therapy-targeting-cd22-heads-to-clinical-trials 2023-02-03T10:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/major-kinase-inhibitor-summit-to-showcase-next-generation-cancer-therapeutics-advances 2023-02-02T06:45:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/major-kinase-inhibitor-summit-to-showcase-next-generation-cancer-therapeutics-advances 2023-02-02T06:45:55+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evaluation-of-ocrelizumab-in-multiple-sclerosis-shows-promising-results 2023-02-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-evaluation-of-ocrelizumab-in-multiple-sclerosis-shows-promising-results 2023-02-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/significant-advances-and-collaborations-among-viva-s-portfolio-companies 2023-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/significant-advances-and-collaborations-among-viva-s-portfolio-companies 2023-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-outcomes-of-panobinostat-in-heavily-pretreated-multiple-myeloma-patients 2023-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-outcomes-of-panobinostat-in-heavily-pretreated-multiple-myeloma-patients 2023-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gsks-anemia-drug-gets-fda-nod-only-for-patients-on-dialysis-bloomberg 2023-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsks-anemia-drug-gets-fda-nod-only-for-patients-on-dialysis-bloomberg 2023-02-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rise-therapeutics-announces-fda-clearance-of-its-ind-application-to 2023-01-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rise-therapeutics-announces-fda-clearance-of-its-ind-application-to 2023-01-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/palbociclib-plus-endocrine-therapy-in-hormone-receptor 2023-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palbociclib-plus-endocrine-therapy-in-hormone-receptor 2023-01-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-elacestrant-as-first-oral-serd-for-advanced-er-her2-breast-cancer 2023-01-27T21:40:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-elacestrant-as-first-oral-serd-for-advanced-er-her2-breast-cancer 2023-01-27T21:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-accepts-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease 2023-01-26T23:30:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-medicines-agency-accepts-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease 2023-01-26T23:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/alleviant-medical-closes-75m-in-financing 2023-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alleviant-medical-closes-75m-in-financing 2023-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/january-2025-fda-brief 2023-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/january-2025-fda-brief 2023-01-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelics-in-medicine-a-renaissance-in-mental-health-treatment 2023-01-25T10:39:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psychedelics-in-medicine-a-renaissance-in-mental-health-treatment 2023-01-25T10:39:46+00:00 weekly 0.7 https://trial.medpath.com/news/ai-driven-hcp-engagement-how-life-sciences-companies-are-optimizing-commercial-success-through-data-analytics 2023-01-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-driven-hcp-engagement-how-life-sciences-companies-are-optimizing-commercial-success-through-data-analytics 2023-01-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-advances-pivotal-study-for-bria-imt-in-metastatic-breast-cancer-following-positive-fda-feedback 2023-01-24T14:16:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/briacell-advances-pivotal-study-for-bria-imt-in-metastatic-breast-cancer-following-positive-fda-feedback 2023-01-24T14:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/artificial-intelligence-enhances-cancer-clinical-trial-enrollment-efficiency 2023-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/artificial-intelligence-enhances-cancer-clinical-trial-enrollment-efficiency 2023-01-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd40-directed-sea-cd40-combo-denotes-antitumor 2023-01-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cd40-directed-sea-cd40-combo-denotes-antitumor 2023-01-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/an-alternative-dosing-strategy-for-ropeginterferon-alfa-2b 2023-01-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-alternative-dosing-strategy-for-ropeginterferon-alfa-2b 2023-01-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ampicillin-proves-effective-against-vre-urinary-tract-infections-despite-resistance-concerns 2023-01-17T08:16:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ampicillin-proves-effective-against-vre-urinary-tract-infections-despite-resistance-concerns 2023-01-17T08:16:30+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-unify-platform-revolutionizes-clinical-trials-with-precision-medicine-and-digital-innovation 2023-01-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-unify-platform-revolutionizes-clinical-trials-with-precision-medicine-and-digital-innovation 2023-01-16T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-3-study-shows-robust-immunogenicity-of-nvx-cov2601-in-vaccine-naive-individuals-with-prior-sars-cov-2-infection 2023-01-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-3-study-shows-robust-immunogenicity-of-nvx-cov2601-in-vaccine-naive-individuals-with-prior-sars-cov-2-infection 2023-01-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-discontinues-moxetumomab-pasudotox-for-hairy-cell-leukemia-due-to-low-clinical-uptake 2023-01-13T16:25:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-discontinues-moxetumomab-pasudotox-for-hairy-cell-leukemia-due-to-low-clinical-uptake 2023-01-13T16:25:58+00:00 weekly 0.7 https://trial.medpath.com/news/could-this-drug-make-your-dog-live-longer-it-just-cleared-a-major 2023-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-this-drug-make-your-dog-live-longer-it-just-cleared-a-major 2023-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-cgrp-targeting-therapy-for-pediatric-migraine-prevention 2023-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-cgrp-targeting-therapy-for-pediatric-migraine-prevention 2023-01-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ima-group-expands-clinical-research-network-with-clinical-trials-of-america-acquisition 2023-01-11T12:06:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ima-group-expands-clinical-research-network-with-clinical-trials-of-america-acquisition 2023-01-11T12:06:20+00:00 weekly 0.7 https://trial.medpath.com/news/ensysce-biosciences-highlights-2022-achievements-and-future-plans-in-shareholder-letter 2023-01-11T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ensysce-biosciences-highlights-2022-achievements-and-future-plans-in-shareholder-letter 2023-01-11T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adimab-announces-2022-clinical-pipeline-update-with-seven-new-partner-programs 2023-01-11T05:09:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adimab-announces-2022-clinical-pipeline-update-with-seven-new-partner-programs 2023-01-11T05:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-summary-axicabtagene-ciloleucel-for-second-line-treatment 2023-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-summary-axicabtagene-ciloleucel-for-second-line-treatment 2023-01-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-novel-tkk1-therapy-for-er-her2-advanced-breast-cancer 2023-01-10T20:03:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-novel-tkk1-therapy-for-er-her2-advanced-breast-cancer 2023-01-10T20:03:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-evaluates-durvalumab-for-bcg-unresponsive-bladder-cancer 2023-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-study-evaluates-durvalumab-for-bcg-unresponsive-bladder-cancer 2023-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stokes-phase-3-trial-of-stk-001-for-dravet-planned-for-next-year 2023-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stokes-phase-3-trial-of-stk-001-for-dravet-planned-for-next-year 2023-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/folfoxiri-plus-cetuximab-or-bevacizumab-as-first-line-treatment-for-brafv600e-mutant-metastatic-colorectal-cancer 2023-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/folfoxiri-plus-cetuximab-or-bevacizumab-as-first-line-treatment-for-brafv600e-mutant-metastatic-colorectal-cancer 2023-01-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xbb-1-5-likely-resistant-to-evusheld-fda-says 2023-01-09T16:00:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xbb-1-5-likely-resistant-to-evusheld-fda-says 2023-01-09T16:00:27+00:00 weekly 0.7 https://trial.medpath.com/news/14-breakthrough-drugs-poised-for-blockbuster-status-by-2027-clarivate-analysis 2023-01-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/14-breakthrough-drugs-poised-for-blockbuster-status-by-2027-clarivate-analysis 2023-01-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-weight-loss-effectiveness-of-glp-1-agonists-in-type-2-diabetes-patients 2023-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-weight-loss-effectiveness-of-glp-1-agonists-in-type-2-diabetes-patients 2023-01-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/syros-pharmaceuticals-inc-nasdaq-syrs-q1-2023-earnings-call-transcript 2023-01-08T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syros-pharmaceuticals-inc-nasdaq-syrs-q1-2023-earnings-call-transcript 2023-01-08T17:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/editas-medicine-inc-nasdaq-edit-q4-2022-earnings-call-transcript 2023-01-08T13:01:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/editas-medicine-inc-nasdaq-edit-q4-2022-earnings-call-transcript 2023-01-08T13:01:57+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-inc-nasdaq-aldx-q4-2022-earnings-call-transcript 2023-01-08T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aldeyra-therapeutics-inc-nasdaq-aldx-q4-2022-earnings-call-transcript 2023-01-08T12:53:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-pulls-eua-granted-to-astrazeneca-s-azn-evusheld 2023-01-08T12:33:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-pulls-eua-granted-to-astrazeneca-s-azn-evusheld 2023-01-08T12:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/geron-corporation-nasdaq-gern-q4-2022-earnings-call-transcript 2023-01-08T10:55:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/geron-corporation-nasdaq-gern-q4-2022-earnings-call-transcript 2023-01-08T10:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-reaches-beyond-cancer-penn-bioengineering-blog 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-reaches-beyond-cancer-penn-bioengineering-blog 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimers-drug-lecanemab-receives-accelerated-approval-amid-safety-concerns-cnn 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimers-drug-lecanemab-receives-accelerated-approval-amid-safety-concerns-cnn 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/combomatch-will-test-new-combinations-of-cancer-drugs-nci 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combomatch-will-test-new-combinations-of-cancer-drugs-nci 2023-01-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/veeva-experts-predict-data-driven-transformation-in-life-sciences-r-d-for-2023 2023-01-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/veeva-experts-predict-data-driven-transformation-in-life-sciences-r-d-for-2023 2023-01-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cilta-cel-garners-more-positive-data-in-early-and-late-relapsed 2023-01-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cilta-cel-garners-more-positive-data-in-early-and-late-relapsed 2023-01-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bioengineered-probiotic-bacteria-could-replace-injections-for-rheumatoid-arthritis-treatment 2023-01-04T18:55:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioengineered-probiotic-bacteria-could-replace-injections-for-rheumatoid-arthritis-treatment 2023-01-04T18:55:45+00:00 weekly 0.7 https://trial.medpath.com/news/first-made-in-singapore-antibody-drug-conjugate-adc-approved 2023-01-04T03:10:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-made-in-singapore-antibody-drug-conjugate-adc-approved 2023-01-04T03:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/european-health-data-space-to-transform-pharmaceutical-research-access-by-2025 2023-01-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-health-data-space-to-transform-pharmaceutical-research-access-by-2025 2023-01-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bdr-pharmaceutical-launches-first-generic-apalutamide-in-india-for-prostate-cancer-treatment 2023-01-03T13:11:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bdr-pharmaceutical-launches-first-generic-apalutamide-in-india-for-prostate-cancer-treatment 2023-01-03T13:11:53+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-clinical-trial-designs-for-glioblastoma-a-new-horizon 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-clinical-trial-designs-for-glioblastoma-a-new-horizon 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-and-molecular-effects-of-oral-ccr4-antagonist 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-and-molecular-effects-of-oral-ccr4-antagonist 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-inebilizumab-in-igg4-related-disease-pubmed 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-inebilizumab-in-igg4-related-disease-pubmed 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clover-biopharmaceuticals-advances-rsv-vaccine-scb-1019-with-u-s-ind-clearance-for-revaccination-study 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clover-biopharmaceuticals-advances-rsv-vaccine-scb-1019-with-u-s-ind-clearance-for-revaccination-study 2023-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-for-hemophilia-a-new-horizon-in-treatment 2022-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-for-hemophilia-a-new-horizon-in-treatment 2022-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-good-use-of-time-providing-evidence-for-how-effort-is-invested-in 2022-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-good-use-of-time-providing-evidence-for-how-effort-is-invested-in 2022-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/emergency-use-authorization-eua-revoked-for 2022-12-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emergency-use-authorization-eua-revoked-for 2022-12-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-in-patients-with-early-alzheimer-s-disease 2022-12-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lecanemab-in-patients-with-early-alzheimer-s-disease 2022-12-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-and-click-therapeutics-expand-digital-therapeutics-alliance-for-schizophrenia-in-460m-deal 2022-12-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-ingelheim-and-click-therapeutics-expand-digital-therapeutics-alliance-for-schizophrenia-in-460m-deal 2022-12-19T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eagle-pharmaceuticals-receives-fda-approval-for-additional-indication-for-pemfexy-r-in-combination-with-pembrolizumab-and-platinum-chemotherapy 2022-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eagle-pharmaceuticals-receives-fda-approval-for-additional-indication-for-pemfexy-r-in-combination-with-pembrolizumab-and-platinum-chemotherapy 2022-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vergent-bioscience-completes-enrollment-in-phase-2-visualize-trial 2022-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vergent-bioscience-completes-enrollment-in-phase-2-visualize-trial 2022-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nadofaragene-firadenovec-for-high-risk-non-muscle-invasive-bladder-cancer 2022-12-16T20:56:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-nadofaragene-firadenovec-for-high-risk-non-muscle-invasive-bladder-cancer 2022-12-16T20:56:59+00:00 weekly 0.7 https://trial.medpath.com/news/renovorx-announces-acceptance-of-four-clinical-data-abstracts-at-the-2023-asco-gastrointestinal-cancers-symposium 2022-12-15T12:30:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/renovorx-announces-acceptance-of-four-clinical-data-abstracts-at-the-2023-asco-gastrointestinal-cancers-symposium 2022-12-15T12:30:43+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-announces-issuance-of-allowance-for-a-u-s-patent-covering-oral-sulopenem 2022-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-announces-issuance-of-allowance-for-a-u-s-patent-covering-oral-sulopenem 2022-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-innovation-commission-charts-path-for-uk-healthcare-transformation-and-life-sciences-growth 2022-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-innovation-commission-charts-path-for-uk-healthcare-transformation-and-life-sciences-growth 2022-12-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/challenges-and-advances-in-alzheimer-s-and-parkinson-s-disease-research 2022-12-13T16:33:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/challenges-and-advances-in-alzheimer-s-and-parkinson-s-disease-research 2022-12-13T16:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/rsv-emerges-as-hidden-threat-to-elderly-population-causing-8000-annual-deaths-in-uk 2022-12-13T09:23:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rsv-emerges-as-hidden-threat-to-elderly-population-causing-8000-annual-deaths-in-uk 2022-12-13T09:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-advances-digital-health-innovation-in-neurology-through-four-pillar-strategy 2022-12-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-advances-digital-health-innovation-in-neurology-through-four-pillar-strategy 2022-12-11T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elranatamab-achieves-61-response-rate-in-heavily-pretreated-multiple-myeloma-patients 2022-12-10T23:00:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elranatamab-achieves-61-response-rate-in-heavily-pretreated-multiple-myeloma-patients 2022-12-10T23:00:37+00:00 weekly 0.7 https://trial.medpath.com/news/agios-presents-updated-pyrukynd-r-mitapivat-data-highlighting-long 2022-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agios-presents-updated-pyrukynd-r-mitapivat-data-highlighting-long 2022-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-assisted-therapy-mediates-psycho-social 2022-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psilocybin-assisted-therapy-mediates-psycho-social 2022-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intrabio-completes-over-enrollment-for-pivotal-niemann-pick-disease-type-c-trial-data-expected-q2-2023 2022-12-08T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intrabio-completes-over-enrollment-for-pivotal-niemann-pick-disease-type-c-trial-data-expected-q2-2023 2022-12-08T13:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-investigational-iptacopan-provides-clinically-meaningful-increases-in-hemoglobin-levels-in-complement-inhibitor-naive-patients-with-pnh 2022-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-investigational-iptacopan-provides-clinically-meaningful-increases-in-hemoglobin-levels-in-complement-inhibitor-naive-patients-with-pnh 2022-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-shows-promise-despite-significant-safety-challenges-in-clinical-trials 2022-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-shows-promise-despite-significant-safety-challenges-in-clinical-trials 2022-12-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-life-sciences-council-lacks-transparency-despite-critical-industry-role 2022-12-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-life-sciences-council-lacks-transparency-despite-critical-industry-role 2022-12-07T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/yonalink-secures-6m-investment-to-transform-clinical-trial-data-management-with-real-time-streaming-technology 2022-12-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yonalink-secures-6m-investment-to-transform-clinical-trial-data-management-with-real-time-streaming-technology 2022-12-05T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/heparegenix-reports-positive-topline-results-of-its-phase-1-clinical 2022-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heparegenix-reports-positive-topline-results-of-its-phase-1-clinical 2022-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-hiv-vaccine-shows-97-antibody-response-rate-in-phase-1-trial 2022-12-01T19:00:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-hiv-vaccine-shows-97-antibody-response-rate-in-phase-1-trial 2022-12-01T19:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-analytics-transform-clinical-trial-design-and-enrollment-strategy 2022-12-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-powered-analytics-transform-clinical-trial-design-and-enrollment-strategy 2022-12-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-olutasidenib-for-acute-myeloid-leukemia-subtype 2022-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-olutasidenib-for-acute-myeloid-leukemia-subtype 2022-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/industry-leaders-push-for-patient-centric-clinical-trials-through-technology-and-community-engagement 2022-11-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/industry-leaders-push-for-patient-centric-clinical-trials-through-technology-and-community-engagement 2022-11-30T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-lecanemab-hailed-as-momentous 2022-11-30T01:05:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-drug-lecanemab-hailed-as-momentous 2022-11-30T01:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/experimental-drug-appears-to-slow-progression-of-alzheimers-disease-in-clinical-trial-but-raises-safety-concerns-cnn 2022-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experimental-drug-appears-to-slow-progression-of-alzheimers-disease-in-clinical-trial-but-raises-safety-concerns-cnn 2022-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-reaches-beyond-cancer-penn-today 2022-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-reaches-beyond-cancer-penn-today 2022-11-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-withdraws-tecentriq-from-bladder-cancer-market-following-failed-confirmatory-trial 2022-11-29T16:26:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-withdraws-tecentriq-from-bladder-cancer-market-following-failed-confirmatory-trial 2022-11-29T16:26:54+00:00 weekly 0.7 https://trial.medpath.com/news/automation-emerges-as-key-solution-to-pharmaceutical-supply-chain-vulnerabilities 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/automation-emerges-as-key-solution-to-pharmaceutical-supply-chain-vulnerabilities 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-development-pipeline-shows-promise-for-als-treatment-with-53-candidates-under-investigation 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-development-pipeline-shows-promise-for-als-treatment-with-53-candidates-under-investigation 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-and-nhs-england-fast-track-novel-prostate-cancer-treatment-darolutamide-combination-therapy 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mhra-and-nhs-england-fast-track-novel-prostate-cancer-treatment-darolutamide-combination-therapy 2022-11-27T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rare-disease-drug-development-faces-critical-forecasting-challenges-with-only-5-having-approved-treatments 2022-11-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rare-disease-drug-development-faces-critical-forecasting-challenges-with-only-5-having-approved-treatments 2022-11-24T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/margetuximab-does-not-surpass-trastuzumab-in-terms-of 2022-11-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/margetuximab-does-not-surpass-trastuzumab-in-terms-of 2022-11-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-teplizumab-first-disease-modifying-drug-for-type-1-diabetes-prevention 2022-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-teplizumab-first-disease-modifying-drug-for-type-1-diabetes-prevention 2022-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fierce-biotech-fda-wants-confirmatory-trials-to-be-underway-before 2022-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fierce-biotech-fda-wants-confirmatory-trials-to-be-underway-before 2022-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/raesedo-inc-awarded-3-4m-sttr-grant-to-develop-new-asthma-therapies 2022-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/raesedo-inc-awarded-3-4m-sttr-grant-to-develop-new-asthma-therapies 2022-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/characteristics-of-measurable-residual-disease-assessment-in-myeloma-a 2022-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/characteristics-of-measurable-residual-disease-assessment-in-myeloma-a 2022-11-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/healthcare-investment-landscape-shows-signs-of-stabilization-after-2021-surge-industry-leaders-report-at-lsx-showcase 2022-11-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healthcare-investment-landscape-shows-signs-of-stabilization-after-2021-surge-industry-leaders-report-at-lsx-showcase 2022-11-14T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-gantenerumab-fails-to-meet-primary-endpoints-in-phase-3-alzheimer-s-trials 2022-11-14T08:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-gantenerumab-fails-to-meet-primary-endpoints-in-phase-3-alzheimer-s-trials 2022-11-14T08:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/viridian-announces-positive-data-from-ongoing-phase-1-2-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted 2022-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viridian-announces-positive-data-from-ongoing-phase-1-2-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted 2022-11-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-starts-pivotal-clinical-trial-with-first-ever-restorative 2022-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xeltis-starts-pivotal-clinical-trial-with-first-ever-restorative 2022-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/paxlovid-may-reduce-risk-of-long-covid-study-suggests 2022-11-09T21:53:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paxlovid-may-reduce-risk-of-long-covid-study-suggests 2022-11-09T21:53:46+00:00 weekly 0.7 https://trial.medpath.com/news/aquatic-vaccines-current-status-and-future-development-prospects-in-global-aquaculture 2022-11-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aquatic-vaccines-current-status-and-future-development-prospects-in-global-aquaculture 2022-11-09T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-regeneron-s-libtayo-combination-for-non-small-cell-lung-cancer-treatment 2022-11-09T12:13:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-regeneron-s-libtayo-combination-for-non-small-cell-lung-cancer-treatment 2022-11-09T12:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-first-line-treatment-patterns-and-outcomes-for-brafv600e-mutant-metastatic-colorectal-cancer-in-europe 2022-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-first-line-treatment-patterns-and-outcomes-for-brafv600e-mutant-metastatic-colorectal-cancer-in-europe 2022-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-mrd-status-and-number-of-remissions-on-hsct-outcomes-aml-hub 2022-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-of-mrd-status-and-number-of-remissions-on-hsct-outcomes-aml-hub 2022-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/baxdrostat-shows-dramatic-blood-pressure-reduction-in-treatment-resistant-hypertension-trial 2022-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/baxdrostat-shows-dramatic-blood-pressure-reduction-in-treatment-resistant-hypertension-trial 2022-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/top-biotech-stocks-for-q2-2023 2022-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-biotech-stocks-for-q2-2023 2022-11-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/treasure-data-releases-whitepaper-on-maximizing-data-utilization-in-pharmaceutical-industry 2022-11-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/treasure-data-releases-whitepaper-on-maximizing-data-utilization-in-pharmaceutical-industry 2022-11-03T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-sues-pfizer-and-biontech-over-mrna-covid-19-vaccine-patent-infringement 2022-11-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-sues-pfizer-and-biontech-over-mrna-covid-19-vaccine-patent-infringement 2022-11-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sirona-completes-enrollment-a-leap-in-the-dcb-treatment-of 2022-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sirona-completes-enrollment-a-leap-in-the-dcb-treatment-of 2022-11-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stem-cell-strategies-show-promise-for-rebuilding-brain-tissue-in-neurodegenerative-diseases 2022-11-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stem-cell-strategies-show-promise-for-rebuilding-brain-tissue-in-neurodegenerative-diseases 2022-11-01T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/small-business-americus-times-recorder-americus-times-recorder 2022-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/small-business-americus-times-recorder-americus-times-recorder 2022-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/topical-tranexamic-acid-reduces-blood-loss-in-knee-arthroplasty-study-finds 2022-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/topical-tranexamic-acid-reduces-blood-loss-in-knee-arthroplasty-study-finds 2022-11-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-invests-92-5m-in-purdue-university-to-advance-pharmaceutical-manufacturing-and-research 2022-10-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-invests-92-5m-in-purdue-university-to-advance-pharmaceutical-manufacturing-and-research 2022-10-31T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/prospective-open-label-single-arm-single-center-follow-up-study-of 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prospective-open-label-single-arm-single-center-follow-up-study-of 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/invitae-study-shows-therapy-informed-by-genetic-testing-reduces-seizures-in-some-patients-with-epilepsy 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invitae-study-shows-therapy-informed-by-genetic-testing-reduces-seizures-in-some-patients-with-epilepsy 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/monoclonal-antibody-prevents-malaria-infection-in-african-adults 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/monoclonal-antibody-prevents-malaria-infection-in-african-adults 2022-10-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/medical-device-advances-in-the-treatment-of-glioblastoma 2022-10-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medical-device-advances-in-the-treatment-of-glioblastoma 2022-10-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genmab-and-abbvie-submit-regulatory-applications-for-epcoritamab-bispecific-antibody-in-relapsed-refractory-b-cell-lymphomas 2022-10-28T12:46:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genmab-and-abbvie-submit-regulatory-applications-for-epcoritamab-bispecific-antibody-in-relapsed-refractory-b-cell-lymphomas 2022-10-28T12:46:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-astrazeneca-s-dual-immunotherapy-combination-for-unresectable-liver-cancer 2022-10-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-astrazeneca-s-dual-immunotherapy-combination-for-unresectable-liver-cancer 2022-10-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-announces-positive-top-line-results-from 2022-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sequana-medical-announces-positive-top-line-results-from 2022-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ivermectin-a-drug-once-touted-as-a-covid-treatment-by-conservatives-doesn-t-improve-recovery-much-clinical-trial-finds 2022-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ivermectin-a-drug-once-touted-as-a-covid-treatment-by-conservatives-doesn-t-improve-recovery-much-clinical-trial-finds 2022-10-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f2g-s-olorofim-shows-44-response-rate-in-phase-2b-trial-for-invasive-fungal-infections 2022-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/f2g-s-olorofim-shows-44-response-rate-in-phase-2b-trial-for-invasive-fungal-infections 2022-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evotec-receives-2-5m-gates-foundation-grant-for-ipsc-based-teratogenicity-platform 2022-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evotec-receives-2-5m-gates-foundation-grant-for-ipsc-based-teratogenicity-platform 2022-10-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intraventricular-b7-h3-car-t-cells-for-diffuse-intrinsic 2022-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intraventricular-b7-h3-car-t-cells-for-diffuse-intrinsic 2022-10-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mereo-biopharma-announces-updated-operating-plan-to-maximize-shareholder-value 2022-10-18T11:06:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mereo-biopharma-announces-updated-operating-plan-to-maximize-shareholder-value 2022-10-18T11:06:14+00:00 weekly 0.7 https://trial.medpath.com/news/nanopharmaceutics-completes-enrollment-in-phase-2-neuroendocrine-tumor-study-combining-triapine-with-lutetium-lu-177-dotatate 2022-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanopharmaceutics-completes-enrollment-in-phase-2-neuroendocrine-tumor-study-combining-triapine-with-lutetium-lu-177-dotatate 2022-10-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-acquires-akouos-for-610m-to-expand-gene-therapy-portfolio-in-hearing-loss-treatment 2022-10-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-acquires-akouos-for-610m-to-expand-gene-therapy-portfolio-in-hearing-loss-treatment 2022-10-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/attralus-enrolls-first-subject-in-phase-1-clinical-trial-for-at-02-a-pan-amyloid-removal-therapeutic 2022-10-17T11:06:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/attralus-enrolls-first-subject-in-phase-1-clinical-trial-for-at-02-a-pan-amyloid-removal-therapeutic 2022-10-17T11:06:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rmat-and-fast-track-designations-to-caribou-s-allogeneic-car-t-therapy-cb-010-for-b-cell-lymphoma 2022-10-14T18:00:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-rmat-and-fast-track-designations-to-caribou-s-allogeneic-car-t-therapy-cb-010-for-b-cell-lymphoma 2022-10-14T18:00:39+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immunotherapy-shows-promise-in-melanoma-treatment-two-studies-demonstrate-improved-outcomes-with-pre-surgery-approach 2022-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-immunotherapy-shows-promise-in-melanoma-treatment-two-studies-demonstrate-improved-outcomes-with-pre-surgery-approach 2022-10-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/significant-improvement-in-overall-survival-with-adjuvant-olaparib-in-high-risk-early-breast-cancer-patients-with-brca1-2-mutations 2022-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/significant-improvement-in-overall-survival-with-adjuvant-olaparib-in-high-risk-early-breast-cancer-patients-with-brca1-2-mutations 2022-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/insulin-glargine-and-liraglutide-show-superior-performance-in-large-type-2-diabetes-comparative-trial 2022-10-07T16:08:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insulin-glargine-and-liraglutide-show-superior-performance-in-large-type-2-diabetes-comparative-trial 2022-10-07T16:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/reproxalap-for-dry-eye-disease-aldeyra-therapeutics-inc 2022-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reproxalap-for-dry-eye-disease-aldeyra-therapeutics-inc 2022-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xeltis-presents-promising-first-in-human-data-on-restorative 2022-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xeltis-presents-promising-first-in-human-data-on-restorative 2022-10-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uab-research-finds-obesity-drug-can-reduce-the-risk-of-type-2-diabetes 2022-10-06T16:39:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uab-research-finds-obesity-drug-can-reduce-the-risk-of-type-2-diabetes 2022-10-06T16:39:00+00:00 weekly 0.7 https://trial.medpath.com/news/aerorx-and-hcmed-partner-to-develop-first-nebulized-laba-lama-combination-for-copd-treatment 2022-10-02T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aerorx-and-hcmed-partner-to-develop-first-nebulized-laba-lama-combination-for-copd-treatment 2022-10-02T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/initial-safety-run-in-results-of-the-phase-3-lotis-5-trial-for-r-r-dlbcl-treatment 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/initial-safety-run-in-results-of-the-phase-3-lotis-5-trial-for-r-r-dlbcl-treatment 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mpn-545-surpass-et-ropeginterferon-alfa-2b-p1101-vs-anagrelide-as 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mpn-545-surpass-et-ropeginterferon-alfa-2b-p1101-vs-anagrelide-as 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-receptor-agonists-show-significant-weight-loss-benefits-in-overweight-and-obese-patients 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-show-significant-weight-loss-benefits-in-overweight-and-obese-patients 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-prospective-single-centre-open-label-single-arm-pilot-study-to 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-prospective-single-centre-open-label-single-arm-pilot-study-to 2022-10-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-watchdog-report-reveals-one-third-of-accelerated-approval-drugs-lack-confirmatory-trial-data 2022-09-30T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-watchdog-report-reveals-one-third-of-accelerated-approval-drugs-lack-confirmatory-trial-data 2022-09-30T04:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-slowing-drug-labelled-historic 2022-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-slowing-drug-labelled-historic 2022-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/photocure-and-karl-storz-launch-advanced-blue-light-cystoscopy-system-in-us-market 2022-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/photocure-and-karl-storz-launch-advanced-blue-light-cystoscopy-system-in-us-market 2022-09-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/population-pharmacokinetic-pharmacodynamic-analyses 2022-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/population-pharmacokinetic-pharmacodynamic-analyses 2022-09-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lipocine-pivots-to-cns-disorders-with-oral-neuroactive-steroid-pipeline 2022-09-26T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lipocine-pivots-to-cns-disorders-with-oral-neuroactive-steroid-pipeline 2022-09-26T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cytokine-profile-at-diagnosis-affecting-trough 2022-09-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokine-profile-at-diagnosis-affecting-trough 2022-09-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/genetically-modified-herpes-virus-shows-promise-against-advanced-cancers-in-early-trial 2022-09-22T23:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genetically-modified-herpes-virus-shows-promise-against-advanced-cancers-in-early-trial 2022-09-22T23:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-study-shows-axicabtagene-ciloleucel-outperforms-tisagenlecleucel-in-relapsed-refractory-dlbcl 2022-09-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-study-shows-axicabtagene-ciloleucel-outperforms-tisagenlecleucel-in-relapsed-refractory-dlbcl 2022-09-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/experts-call-for-reform-in-experimental-treatment-access-balancing-patient-rights-with-sustainable-development 2022-09-17T04:21:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-call-for-reform-in-experimental-treatment-access-balancing-patient-rights-with-sustainable-development 2022-09-17T04:21:54+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-for-affinity-enhanced-t-cell-therapy-in-synovial-sarcoma 2022-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-for-affinity-enhanced-t-cell-therapy-in-synovial-sarcoma 2022-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adeno-associated-virus-gene-therapy-for-hemophilia-a-new-therapeutic-paradigm 2022-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adeno-associated-virus-gene-therapy-for-hemophilia-a-new-therapeutic-paradigm 2022-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/synergia-medical-secures-eur9-million-in-series-b-funding-for-epilepsy-treatment-innovation 2022-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synergia-medical-secures-eur9-million-in-series-b-funding-for-epilepsy-treatment-innovation 2022-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-mersana-therapeutics-xmt-1660-for-triple-negative-breast-cancer-treatment 2022-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-mersana-therapeutics-xmt-1660-for-triple-negative-breast-cancer-treatment 2022-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/low-dose-interleukin-2-shows-promise-in-slowing-motor-neurone-disease-progression-in-landmark-mirocals-trial 2022-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-dose-interleukin-2-shows-promise-in-slowing-motor-neurone-disease-progression-in-landmark-mirocals-trial 2022-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tecvayli-shows-promising-outcomes-in-treating-advanced-multiple-myeloma 2022-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tecvayli-shows-promising-outcomes-in-treating-advanced-multiple-myeloma 2022-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/entrepreneurial-accelerator-program-eap-portfolio-company-receives-400000-research-grant-from-the-national-cancer-institute-to-study-a-repurposed-drug-in-treatment-of-glioblastoma 2022-09-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/entrepreneurial-accelerator-program-eap-portfolio-company-receives-400000-research-grant-from-the-national-cancer-institute-to-study-a-repurposed-drug-in-treatment-of-glioblastoma 2022-09-08T00:00:00+00:00 weekly 0.7